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Idiopathic pulmonary fibrosis (IPF) is a fatal progressive chronic disease 
characterised by excessing scarring of the lungs leading to irreversible decline 
in lung function. The aetiology and pathogenesis of the disease are still 
unclear, although lung fibroblast activation and secretion of fibrotic and 
inflammatory mediators have been strongly associated with the development 
and progression of IPF. Significantly, long non-coding RNAs (lncRNAs) are 
emerging as novel modulators of multiple biological processes although their 
function and mechanism of action is poorly understood and their role in IPF is 
uncharacterised. 
 
To better understand the underlying pathological features of IPF, the 
phenotypic changes of control and IPF lung fibroblasts as well as the role of 
lncRNAs in IPF and during TGF-β1, PDGF-AB and IL-1β-induced activation 
of lung fibroblasts were examined. Overall, IPF fibroblasts demonstrated an 
increased fibrotic and a reduced inflammatory and proliferative profile 
compared to controls. The phenotypic differences of control and IPF 
fibroblasts were also reflected at the epigenetic level. Using chromatin 
immunoprecipitation combined with sequencing (ChIP-seq), the distribution 
profile of the histone modification H3K4me1 was shown to be notably different 
between the two fibroblast populations. 
 
RNA-sequencing (RNA-seq) and microarray technology identified several 
differentially expressed lncRNAs in lung fibroblasts upon TGF-β1 and IL-1β 
activation. Subsequent knockdown studies focused on the functional roles of 
four lncRNAs namely LINC00960, LINC01140, IL7AS and MIR3142HG. 
LINC01140 was found to be a negative regulator of the inflammatory 
response, while both LINC00960 and LINC01140 were shown to be positive 
regulators of proliferation. Additionally, IL7AS and MIR3142HG were also 
shown to regulate the inflammatory response in control and IPF fibroblasts. 
Collectively, the results of this thesis propose that lncRNAs may be important 
regulators of lung fibroblast functions and consequently mediate the 
progression of IPF. 
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1.1. The respiratory system 
 
The respiratory system is a complex and highly organised organ system 
consisting of multiple different cell types that are required for gas exchange 
i.e. the uptake of oxygen and release of carbon dioxide from the blood. Its 
association with disease was first acknowledged in the Hippocratic corpus, in 
which Hippocrates documents the concept of symptoms and diagnosis of 
pulmonary infections around the 5th- 4th century BC (Tsoucalas and Sgantzos, 
2016). However, the function of respiratory organs appears to have been first 
explored by Erasistratus, a Greek physician, in 280 BC. He supposed that the 
pneuma (circulating air or ‘spirit’ translated from ancient Greek) could enter 
the body through the lungs in the process of inhalation. Although his work was 
challenged by Galen and other scientists centuries later, he undoubtedly laid 
the foundations of respiratory research (Pearce, 2013). The notion of 
breathing was difficult to comprehend for hundreds of years and it was 
therefore a topic to be challenged systematically. However, the discovery of 
oxygen was a breakthrough for our understanding of respiration and provided 
the path for continuous progress in respiratory research. Therefore, since the 
early investigations of lung function, modern pulmonology and scientific 
research has developed dramatically our knowledge of respiration, an 
essential human physiological process.  
 
Indeed, we now understand that gas exchange requires the respiratory and 
circulatory systems to work together to transport oxygen and carbon dioxide 
to and from the lungs. Briefly, upon inhalation air enters the body through the 
nose or mouth where air rich in oxygen travels to the lungs via the pharynx 
and trachea which branches into the bronchi, the left and right bronchus. The 
bronchi serve as airway passages which enter the lungs and further divide 
into the bronchioles in tree-like structures. These define the end of the 
conducting zone and the start of the respiratory zone of the respiratory tract. 
The terminal structure of the respiratory bronchioles are the pulmonary alveoli 
which are the primary site of gas exchange in the lungs. At this anatomical 
structure, the alveolar ducts connect the respiratory bronchioles to the air sacs 
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which contain the alveoli, the smallest units of the respiratory tract. The alveoli 
are composed of Type I and II alveolar epithelial cells (AECs) and 
macrophages and are covered by capillaries. The alveolar epithelium and 
endothelial cells of the capillaries compose the very thin gas permeable 
membrane barrier, also known as the blood-air barrier, where the process of 
gas exchange occurs by simple diffusion.  The membrane is characterised by 
its elasticity to allow the alveoli to stretch during inhalation and exhalation. The 
barrier allows oxygen carried from the alveoli to diffuse into the circulation via 
the capillaries and carbon dioxide out of the capillaries back to the alveoli.  
 
The airways and alveoli are surrounded and protected by layers of tissue 
consisting of nearly 50 cell types (Breeze and Wheeldon, 1977). These assist 
with the various structural and functional needs of the respiratory area and 
include cells such as lung fibroblasts, epithelial, smooth muscle and 
inflammatory cells (Hogan et al., 2014). Maintaining homeostasis in this 
environment is crucial during respiration as well as response to injury and 
infections (Thompson et al., 1995).   
 
The development of the respiratory system begins at embryogenesis and 
continues until early adolescence through controlled cell proliferation and 
differentiation. Although infant lungs can sustain life after birth, respiratory 
development is a long process which takes several years to complete 
(Pinkerton, 2000). The embryonic, pseudoglandular, canalicular, saccular, 
and alveolar stages are essential developmental stages for the growth of the 
fully functional and complex respiratory structures (Burri, 1984). Several 
studies have even shown that genetic or environmental stimuli that may 
interfere at any time with respiratory development result in an increased risk 
of lung dysfunction and disease in later life (Kajekar, 2007; Macneal and 







1.1.1. Interstitial lung diseases 
Interstitial lung diseases (ILD), more specifically known as heterogeneous 
diffuse parenchymal lung diseases (DPLD), are a group of heterogeneous 
lung diseases which share similar clinical and pathophysiological features. 
ILDs are a large group of mostly chronic but also acute lung diseases 
characterised by variable degrees of inflammation and fibrosis of the lung 
interstitium (Meyer et al., 2012). The cause of ILDs can be either identifiable 
or unknown, as in the case of idiopathic pulmonary fibrosis (IPF) (American 
Thoracic Society European Respiratory Society, 2002). Exposure to fumes, 
dust, radiation, microbes and other occupational and environmental allergens 
or hazards have been identified as triggers for the development of ILDs. 
Additionally, granulomatous inflammation as well as autoimmune and genetic 
diseases have also been found to play a role in the development of ILDs 
(Mikolasch et al., 2017).  
 
Over a hundred types of ILDs have been described, each one displaying an 
array of unique pathophysiological processes. The complexity of these 
diseases and their tendency to display similar phenotypes means  
distinguishing between the different types of ILDs can be challenging 
(American Thoracic Society European Respiratory Society, 2002). Therefore, 
a robust collection of physical and medical tests as well as a detailed medical 
history are important to establish an accurate diagnosis. Successful 
management of ILDs is very much diagnosis-dependent, as different types of 
ILDs require specific and targeted therapeutic approaches (Meyer, 2014).  
 
IPF is considered to be the most common of the ILDs, and it more accurately 
fits into the sub-group of idiopathic interstitial pneumonias (IIPs) (Raghu et al., 
2011; Kekevian et al., 2014). The National Institute for Health and Care 
Excellence (NICE) regularly updates its guidelines for respiratory physicians 
and other professionals as well as information and recommendations to the 
public. The guidelines are updated according to new clinical and research 
evidence which are summarised in these documents. The American Thoracic 
Society (ATS) and the European Respiratory Society (ERS) also provide 
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official guidelines for the diagnosis and management of IIPs (Meyer et al., 
2012; Travis et al., 2013; American Thoracic Society European Respiratory 
Society, 2002).  
 
Over the past decades, IPF has garnered increasing attention within the 
clinical and research sphere in light of significantly increased incidence. 
Mortality and morbidity rates in the United States have been on the rise 
between 1992 and 2003 (American Thoracic Society European Respiratory 
Society, 2002; Olson et al., 2007). Likewise, IPF cases have doubled in the 
UK between 1990 and 2003 and evidence suggests that incidence will 
continue to increase in the future (Gribbin et al., 2006; Lee et al., 2014).  
 
1.2. Idiopathic pulmonary fibrosis 
Fibrosis is a pathophysiological condition that can affect nearly every organ in 
the human body where irregular and excessive accumulation of scar tissue 
leads to organ failure and potentially death as seen in the final stages of 
fibrotic diseases such as pulmonary (King et al., 2011), cardiac (Kong et al., 
2014), nephrotic (Duffield, 2014) and hepatic fibrosis (Bataller and Brenner, 
2005). In combination with genetic factors, tissue injuries may provoke the 
development of fibrosis including exposure to damaging environmental stimuli 
such as irritants, smoke, radiation, viral and bacterial infections (Raghu et al., 
2011; Macneal and Schwartz, 2012). 
  
IPF is a progressive chronic ILD which is characterised by scar tissue 
accumulation and therefore thickening of the normal lung walls, leading to 
impaired gas exchange and restricted ventilation.  IPF is a disease of 
unknown aetiology, making development of effective drug treatments 
particularly challenging (Raghu et al., 2011). Nonetheless, scientists have 
been intensively  researching the molecular and cellular mechanisms of the 
disease and although the pathogenesis of IPF is still unclear, several theories 
regarding the pathophysiology of IPF have been proposed (Todd et al., 2012).  
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As is the case with most ILDs, inflammation was initially thought to be the 
major player in IPF until unresponsiveness to anti-inflammatory medications 
prompted the re-evaluation of this idiom (Richeldi et al., 2003; Davies et al., 
2003). However, the presence of immune cells in IPF lungs has been a 
consistent pathological finding and  may  be important in the development of 
the disease (King et al., 2001b; Gross and Hunninghake, 2001; Katzenstein 
and Myers, 1998; Balestro et al., 2016; Travis et al., 2013).  
 
The histology of fibrotic lungs indicates irreversible accumulation of scarred 
tissue characterised by collagen deposition and other alterations to the 
extracellular matrix (ECM) which dramatically remodels the lung architecture 
by stiffening the distal airspaces and parenchyma (Raghu et al., 2011). It has 
been  suggested that lung fibrosis could be provoked by a number of different 
cell types including epithelial cells, fibroblasts, myofibroblasts and immune 
cells (King et al., 2011).  
 
1.2.1. Epidemiology 
It has been challenging to accurately assess the incidence and prevalence of 
IPF as there is limited epidemiological data on the disease, an issue that is 
compounded by the regular changes to the diagnostic criteria. As such, 
estimates vary as a result of demographic differences, study population and 
the case definition used to identify patients with IPF (Nalysnyk et al., 2012).  
 
Studies in the United States (Raghu et al., 2016), Canada (Hopkins et al., 
2016) and Europe, including Greece (Karakatsani et al., 2009), Finland 
(Hodgson, 2002), Norway (Plessen et al., 2003) and the United Kingdom 
(Gribbin et al., 2006; Navaratnam et al., 2011), have reported widely different 
incidence and prevalence of IPF. Interestingly, a meta-analysis of 34 studies 
by Hutchinson et al. (Hutchinson et al., 2015) suggests that incidence of IPF 
is currently comparable to malignancies such as testicular, stomach liver and 
cervical cancers. A systematic review by Nalysnyk et al. analysed 15 studies 
of the incidence and prevalence of IPF in the United States and Europe 
(Nalysnyk et al., 2012). Using narrow case definitions of IPF, an estimate of 
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14.9 to 27.9 per 100,000 people live with IPF in the United States, while the 
estimate increases to 42.7 to 63 per 100,000 people when using broad case 
definitions. Similarly, the incidence of new cases varied from 6.8 to 8.8 per 
100,000 per year using narrow case definitions and 16.3 to 17.4 per 100,000 
people per year using broad IPF definitions (Nalysnyk et al., 2012). In Europe, 
approximately 1.25 to 23.4 per 100,000 people suffer with the disease while 
incidence ranges from 0.22 to 7.94 per 100,000 people every year (Nalysnyk 
et al., 2012). In the United Kingdom, more recent data from the British Lung 
Foundation reported approximately 32,479 living with IPF, 7,865 new cases 
of IPF and 5,292 deaths in 2012 which may give a better insight on the annual 
numbers of incidence, prevalence and mortality (British Lung Foundation, 
2018). Additionally, a more recent study by Raghu et al. (Raghu et al., 2016) 
demonstrated a similar incidence and prevalence of IPF in the United States.  
 
Despite the discrepancies relating to disease definition, study population and 
design, there is clear and consistent evidence that IPF incidence and 
prevalence are increasing in most countries worldwide (Olson et al., 2007; 
Navaratnam et al., 2011; Nalysnyk et al., 2012; Raghu et al., 2016; Ley et al., 
2011; Ley and Collard, 2013). IPF has the worst prognosis of all ILDs with 
median survival ranging between 2.5 to 3.5 years after diagnosis, with some 
studies reporting up to around 5 years depending on the diagnostic criteria 
and the stage of the disease at the time of diagnosis (Ley et al., 2011; Collard 
et al., 2003; Fernández Pérez et al., 2010). Interestingly, comparing statistics 
from the US National Cancer Institute (Vancheri et al., 2010) and IPF (Olson 
et al., 2007), survival rates of IPF appear to be worse compared to several 
types of cancer. The clinical course of IPF patients varies from slow 
progression to rapid deterioration and death depending on disease 
progression (Barlo et al., 2010). Thus, the course of IPF is unpredictable and 
it can be difficult to predict patterns of disease progression. 
 
Studies have also focused on the influence of age and sex upon IPF 
occurrence; showing higher incidence amongst the elderly population (55-64 
years old) as well as males compared to females (incidence rate ratio 1.08) 
(Raghu et al., 2016). IPF incidence and mortality rates have been previously 
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shown to be higher in men and also to increase with age (Olson et al., 2007; 
Navaratnam et al., 2011). The epidemiology study by Olson et al. has also 
shown that incidence appears to be higher within the white, non-Hispanic 
population, suggesting a role for race and ethnicity (Olson et al., 2007). Apart 
from sex, age and race, several additional risk factors have been linked with 
the development of the disease. Exposure to cigarette smoke  (Baumgartner 
et al., 1997), metal and wood dust  (Paolocci et al., 2018; Koo et al., 2017) as 
well as microbial infections (Molyneaux et al., 2014) are some of the 
environmental factors associated with IPF (Ley and Collard, 2013). Several 
occupations have also been linked with the development of IPF such as 
hairdressing, farming, agriculture and livestock handling (Baumgartner et al., 
2000). Genetically susceptible individuals carrying IPF-associated gene 
mutations have also been shown to be more prone to developing the disease, 
possibly via interactions between environmental, occupational and genetic 
stressors (Steele and Schwartz, 2013). A number of comorbidities are also 
associated with IPF including lung cancer, pulmonary hypertension, 
emphysema, gastroesophageal reflux and cardiovascular disease (Lee et al., 
2014).  
 
1.2.2. IPF symptoms 
IPF induces exertional dyspnoea, a feeling of breathlessness, which is one of 
the most common symptoms experienced. Dyspnoea is often accompanied 
with a non-productive dry cough which progressively worsens over time until 
it becomes clear to patients that their daily functionality is compromised. 
Pulmonary malfunction due to fibrosis may induce other symptoms such as 
inspiratory crackles, chest discomfort, finger clubbing, weakness and loss of 
appetite  (King et al., 2001a; Oldham and Noth, 2014; Meltzer and Noble, 
2008). Unfortunately, the presentation of IPF is often confused with other 






1.2.3. IPF diagnosis 
The clinical presentation of IPF especially in the initial stages, may be 
unspecific and therefore a multidisciplinary team is required to rule out other 
types of ILDs. As such, exclusion of other ILDs with a known cause and a 
similar interstitial pneumonia pattern is of crucial importance and the first step 
towards diagnosis of IPF. Blood tests may detect the presence of serological 
biomarkers and autoantibodies present in other types of ILDs such as 
connective tissue disease-associated ILDs (Mikolasch et al., 2017). Initial 
investigations may also include pulmonary function tests (PFT) which are 
often useful for assessing the severity of the disease as well as directing 
further diagnostic tests. PFTs may give a better insight on the reduction of 
total lung capacity (TLC), forced vital capacity (FVC) and diffusing carbon 
monoxide (DLCO) capacity. Additional physical tests include exercise tests 
such as the 6-minute walk test which are used to determine abnormalities in 
oxygen transfer and gas exchange in the lungs (Ley et al., 2011). 
 
However, in order to reach a consensus diagnosis of IPF, further 
investigations based on radiological and histological evidence are required. 
Medical imaging such as chest X-rays or high resolution computed 
tomography (HRCT) enable detection of the presence of an usual interstitial 
pattern, a key histological characteristic of IPF lungs (Mikolasch et al., 2017). 
HRCT has now become a standard test as it can provide invaluable 
information and a more detailed evaluation of the extent of fibrosis compared 
to x-rays which are more antiquated and may lack diagnostic reliability in this 
context. Using HRCT has improved the overall diagnostic accuracy of IPF and 
reduced the necessity for more invasive tests such as surgical lung biopsies, 
a relatively higher risk procedure that not all patients may be fit enough to 
partake in. Typical HRCT shows features of interstitial pneumonia including 
honeycombing with sub-pleural and basal abnormalities, reticular opacities 
and often traction bronchiectasis. Additionally, bronchoalveolar lavage (BAL) 
may be undertaken to examine total cell counts, infection or the presence of 
malignant cells in order to exclude other causes of ILDs. In some cases, a 
surgical lung biopsy may be recommended to confirm diagnosis in patients 
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where HRCT fails to detect the presence of a definite IPF pattern. Tissue 
obtained from biopsies may provide further histological evidence of 
honeycombing, fibrosis and scarring in the pulmonary parenchyma (Meltzer 
and Noble, 2008; Oldham and Noth, 2014; Sgalla et al., 2016).  
 
Updated guidelines for the diagnosis and management of IPF have been 
published in 2011 in a joint effort from the ATS, ERS, the Japanese 
Respiratory and Latin-American Thoracic societies (Raghu et al., 2011).  
 
1.2.4. The pathogenesis of IPF 
Under physiological conditions, fibrogenesis is initiated in response to tissue 
injury and forms part of the wound repair process involved in the restoration 
of homeostasis. Fibrogenesis is commonly initiated by epithelial injury, leading 
to activation of the coagulation and inflammation cascades. This in turn results 
in the activation, recruitment and proliferation of fibroblasts that are 
responsible for the release of ECM components. In the final remodelling 
stage, the wound area is resolved and normal tissue structure and structural 
integrity is restored (Strieter, 2008).  
 
During the fibrosis associated with IPF, any stage of the wound repair process 
may be dysregulated (Figure 1), resulting in the irreversible accumulation of 
scar tissue. These fibrotic areas are characterised by an overproduction of 
ECM components, predominantly collagen as well as other fibrotic proteins, 
which dramatically remodels the lung architecture and leads to excessive 
scarring (Wynn, 2011). The secretion of several pro-fibrotic cytokines and 
growth factors are thought to be crucial mediators of fibrosis. These drive the 
migration, proliferation and activation of mesenchymal cells which ultimately 
results in the differentiation of fibroblasts into α-smooth muscle actin (α-SMA)-
expressing myofibroblasts and the development of fibrotic foci, a dense 
collection of myofibroblasts and scar tissue (Hinz et al., 2007). The pleiotropic 
growth factor TGF-β1 (transforming growth factor β1) is regarded as a key 
player of fibrosis (Desmoulière et al., 1993) along with other mediators such 
as platelet-derived growth factor (PDGF) (Antoniades et al., 1990), interleukin 
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1β (IL-1β) (Zhang et al., 1993) and several chemokines (Sahin and Wasmuth, 
2013) and cytokines (Borthwick et al., 2013).  
 
Figure 1. Overview of the most significant wound healing stages leading 
to the development of IPF. Epithelial cell injury leads to the secretion of 
inflammatory mediators and triggers platelet activation which results in 
enhanced vessel permeability for the recruitment of leukocytes. These 
inflammatory cells release pro-fibrotic cytokines such as TGF-β1 that mediate 
the activation and recruitment of fibroblasts as well as their differentiation into 
myofibroblasts and the subsequent release of ECM components to promote 
wound healing. In IPF, an aberrant wound repair response leads to the 
irreversible formation of excessive scar tissue in the lungs.  
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At the present time, the drivers of the aberrant wound healing process leading 
to fibrosis are unknown. However, certain cells types such as alveolar 
epithelial cells and fibroblasts, as well as a dysregulated coagulation and 
inflammatory response have been implicated in disease initiation and 
progression (King et al., 2011; Sgalla et al., 2018; Kendall and Feghali-
Bostwick, 2014; Martinez et al., 2017).  
 
1.2.4.1. Alveolar epithelial injury 
Prior to the activation of fibroblasts, it is believed that type I AECs maybe 
subjected to repetitive injury, which causes damage to the delicate epithelium 
structure. Type I AECs line more than 90% of the alveolar surface and 
damage promotes the activation and proliferation of the surfactant-producing 
type II AECs (Shannon and Hyatt, 2004). This results in hyperplasia of the 
type II AECs in order to cover the exposed alveolar surface, as well as the 
activation of local coagulation pathways and the initiation of a provisional 
matrix also known as a wound clot (Chambers, 2008a).  
 
During the normal healing process, the lung tissue will eventually regain its 
original structure and function as the provisional matrix gradually dissipates. 
In the case of injury of the type I AECs, the hyperplastic type II AECs are 
thought to undergo regulated apoptosis and trans-differentiation into type I 
AECs in order to re-establish a fully functional alveolar epithelium (Selman 
and Pardo, 2006).  
 
However, if the epithelial basement membrane remains disturbed following 
extensive damage, the alveoli can collapse and type II AECs fail to undergo 
re-epithelisation. An aberrant wound repair response may then be initiated 
during which the epithelial cells, predominantly type II AECs, are thought to 
release several pro-fibrotic cytokines, growth factors and other chemokines at 
the site of injury (Allen and Spiteri, 2002). The epithelial injury is then thought 
to ultimately promote the activation and proliferation of fibroblasts and 
myofibroblasts and the formation of a stiffened ECM in IPF (Camelo et al., 
2014; Kasper and Barth, 2017). 
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1.2.4.2. Coagulation 
In the initial stages of wound repair, circulating platelets are activated via the 
coagulation cascade to promote platelet aggregation and the formation of 
cross-linked fibrin strands at the site of injury (Crooks et al., 2014). The 
coagulation cascade is tightly regulated by endogenous anti-coagulants and 
the action of thrombin (Chambers, 2008a). Fibrin deposition was shown to be 
present in the lungs of IPF patients whilst other reports have shown elevated 
expression of Tissue Factor (TF) in type II AECs (Imokawa et al., 1997) and 
BAL fluid (Kotani et al., 1995). 
 
Upon tissue injury, TF forms the TF-activated factor VIIa (FVIIa) to initiate the 
coagulation cascade. The coagulation cascade is a complex process, but TF-
FVIIa complex ultimately triggers the activation of factor X (FX) to factor Xa 
(FXa); FXa in association with activated factor V (FVa) leads to the conversion 
of prothrombin to thrombin, which in turn converts fibrinogen to fibrin resulting 
in the subsequent formation of a wound clot. Interestingly, a study by Scotton 
et al. (Scotton et al., 2009) demonstrated elevated expression of FX and the 
proteinase FXa in the bleomycin-induced fibrotic lungs. FXa was shown to 
contribute to driving the fibrotic response by inducing myofibroblast 
differentiation via a TGF-β-dependent mechanism, involving the thrombin 
receptor and proteinase-activated receptor-1 (PAR1).  
 
Fibrin may be broken during the process of fibrinolysis via the activation of 
plasmin. Plasmin is converted from plasminogen by the action of proteinases, 
urokinase-type plasminogen activator and tissue-type plasminogen activator 
(Chambers, 2008b). Studies have shown that inhibitors of this pathway such 
as plasminogen activator inhibitor 1 (PAI-1) are elevated in IPF patients 
(Kotani et al., 1995) and bleomycin-induced fibrosis (Eitzman et al., 1996) 
indicating a pro-coagulant activity in IPF lungs (Crooks and Hart, 2015).  
Based upon these observations, the process of coagulation has been targeted 
for potential therapeutics, although anti-coagulants are still not recommended 
for IPF patients (Raghu et al., 2011). 
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1.2.4.3. Inflammation  
One of the initial concepts relating to IPF pathogenesis was that the disease 
was initiated and driven by chronic inflammation. However, the role of 
inflammation was questioned when anti-inflammatory and 
immunosuppressant therapies failed to improve lung function and survival of 
IPF patients.  A study of 330 IPF patients showed no effect on progression-
free survival when treated with the immune-regulatory cytokine Interferon 
gamma-1β (IFN-γ-1β) (Raghu et al., 2004). Additionally, the INSPIRE 
randomised double-blinded placebo-controlled trial of IFN-γ-1β did not show 
any benefit compared to the placebo and was terminated (King et al., 2009). 
The IFIGENIA trial, a double-blind, randomised, placebo-controlled study 
assessed the efficacy of N-Acetylcysteine (NAC) added to prednisone and 
azathioprine (Demedts et al., 2005), however the survival benefit of IPF 
patients was questioned. The follow-on PANTHER trial was designed to 
address some of the issues of the IFIGENIA trial and evaluated the response 
in IPF patients of this triple therapy, but was terminated  prematurely when  it 
showed significantly increased mortality (Idiopathic Pulmonary Fibrosis 
Clinical Research Network et al., 2012). The study continued as a two-group 
study (NAC vs. placebo) but demonstrated no benefit to IPF patients 
(Martinez, 2014). 
 
Whilst the role of inflammation in the initiation and progression of the disease  
remains unclear, there is  plenty of evidence to indicate that IPF is associated 
with inflammation and changes in the innate and adaptive immune response 
(Wick et al., 2013). Studies have shown that expression of inflammatory 
chemokine (C-C motif) ligands (CCL) such as CCL2 (Antoniades et al., 1992), 
CCL11 (Huaux et al., 2005) and CCL8 (Lee et al., 2017) are elevated in fibrotic 
lungs. The secretion of the pro-inflammatory cytokine IL-1β has been linked 
to the progression and development of fibrosis by enhancing the expression 
of the inflammatory mediators interleukin 6 (IL-6) and tumor necrosis factor α 
(TNF-α), disrupting alveolar architecture and  by increasing pulmonary 
fibroblasts and collagen deposition (Kolb et al., 2001). Release of the pro-
fibrotic cytokines TGF-β1 and PDGF may also be stimulated by IL-1β in BAL 
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fluid (Kolb et al., 2001). IL-1β was also shown to increase the infiltration of 
neutrophils and macrophages to the lungs (Kolb et al., 2001; Lappalainen et 
al., 2005) and elevate the expression of matrix metalloproteinases (MMPs) 
MMP-9/12 and chemokine (C-X-C motif) ligands (CXCL) CXCL1/2 
(Lappalainen et al., 2005).  
 
Inflammatory cells found in the lungs of IPF patients were shown to produce 
elevated levels of reactive oxygen species (ROS) which are thought to 
contribute to tissue damage in IPF (Cantin et al., 1987; Strausz et al., 1990). 
Mitochondria-derived ROS may also drive pro-inflammatory cytokine 
production including IL-1β expression (Naik and Dixit, 2011). ROS production 
was shown to be regulated by TGF-β1 and to further mediate downstream 
cellular events such as IL-6 expression (Junn et al., 2000) and activation of 
PAI-1 (Vayalil et al., 2007), an important regulator of ECM degradation. As 
such, in this environment where fibrotic and inflammatory mediators work 
together, an acute lung injury may readily escalate into a chronic fibrotic 
response; thus, controlling the acute inflammatory activity may prove 
beneficial in eliminating the downstream effects of a chronic progressive 
fibrotic state.  
 
The adaptive immune response has also been linked to the development of 
IPF. Interestingly, the pro-inflammatory cytokine interleukin 17A (IL-17A) 
which is expressed by CD4+ T-helper (TH-17) cells, has been linked with 
enhanced neutrophil recruitment, also known as neutrophilia, as well as TGF-
dependent and IL-1β-driven fibrosis (Wilson et al., 2010). Notably, a study by 
Kinder et al. demonstrated that elevated levels of neutrophils in BAL fluid was 
shown to be a prognostic predictor of early mortality in IPF patients (Kinder et 
al., 2008). Additionally, TH-1 effector T cells are thought to exert anti-fibrotic 
activities through the production of IFN-γ, which was shown to attenuate 
fibrosis (Baroni et al., 1996) by inhibiting TGF-β-induced phosphorylation of 
Smad3 (Ulloa et al., 1999). TH-2 effector T cells are thought to promote fibrosis 
via the production of pro-inflammatory cytokines such as interleukin 13 (IL-13) 
which stimulates collagen deposition in fibroblasts (Chiaramonte et al., 1999).  
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In this environment, activated platelets, damaged epithelial cells and recruited 
inflammatory cells release more pro-fibrotic growth factors such TGF-β1 that 
drive the fibrotic response. TGF-β1 is considered the driving force of fibrosis 
as it has multiple properties including activation of fibroblasts, epithelial cell 
differentiation via epithelial-mesenchymal transition (EMT) and even 
stimulation of the expression of pro-inflammatory cytokines such as IL-1β to 
further enhance the fibrotic response (Wynn and Ramalingam, 2012). 
 
1.2.4.4. Lung fibroblasts 
Lung fibroblasts are also activated in response to epithelial injury and thought 
to be important in the development of pulmonary fibrosis. Fibroblasts are 
activated at the site of injury following the release of pro-fibrotic mediators 
such as TGF-β1 (Border and Noble, 1994). Under  these pathologic 
conditions, fibroblasts may differentiate into myofibroblasts, a cell type that is 
associated with the fibrotic lung and predominantly located within fibrotic foci 
(Kuhn and McDonald, 1991; Zhang et al., 1994). Myofibroblasts share 
features with smooth muscle cells as they express α-SMA stress fibres and 
present a more contractile and pro-fibrotic potential phenotype (Hinz et al., 
2001). Specifically, they are believed to secrete excessive amounts of ECM 
components such as collagen, hyaluronic acid, elastin, proteoglycans and 
other proteins that are deposited in the ECM (King et al., 2011; Pardo and 
Selman, 2016).  
 
Myofibroblasts that accumulate in the lungs of IPF patients are a central 
feature of the disease and are thought to originate from at least three different 
sources. The most prominent and straightforward source is the proliferation 
and differentiation of resident fibroblasts following the release of pro-fibrotic 
mediators such as TGF-β1 (Desmoulière et al., 1993). Pro-fibrotic mediators 
also promote the influx and migration of circulating fibrocytes to the wound 
site (Abe et al., 2001). Fibrocytes are bone marrow mesenchymal cells which 
are present in the blood and tissues in a relatively inactive state until 
chemotactic stimuli such as CXCL12 promote their migration to the lungs 
where they can contribute to the development of pulmonary fibrosis (Phillips 
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et al., 2004) and give rise to collagen-producing fibroblasts (Hashimoto et al., 
2004). Finally, it has been proposed that alveolar epithelial cells may acquire 
mesenchymal phenotypes via the process of EMT, during which they lose 
their epithelial cell markers and transform into fibroblast-like cells as 
demonstrated by Kim et al. (Kim et al., 2006). EMT-mediated formation of 
fibroblasts was also shown to be regulated by exposure to TGF-β1 (Willis et 
al., 2005), indicating the possibility of epithelial cells serving as a source of 
myofibroblasts. The contribution of fibrocytes, EMT and other cell types such 
as pericytes (Hung et al., 2013) to the fibroblast population in the progression 
of IPF is still unclear. 
 
1.2.4.5. The fibrotic response and ECM remodelling phase 
The aberrant wound healing response in IPF involves several underling 
mechanisms which are thought to drive the disease. However, the most well-
established and studied concept is the role of TGF-β1 in the development of 
fibrosis and its effect on fibroblasts and the ECM which play a major role in 
the fibrotic cascade (Roberts et al., 1986). TGF-β1 activates a complex 
network of intracellular pathways and exhibits several properties that are 
thought to  promote fibrosis such as EMT (Willis et al., 2005), apoptosis (Kim 
et al., 2006), as well as recruitment and proliferation of fibroblasts via PDGF 
expression which can also release more TGF-β1 (Scotton and Chambers, 
2007). TGF-β1 is secreted by most cells, however AECs are the main source 
of TGF-β1 during the initial stages of wound repair. TGF-β1 may also regulate 
the expression of several pro-inflammatory and pro-fibrotic mediators  and 
work with them synergistically to further enhance the fibrotic response 
(Fernandez and Eickelberg, 2012).  
 
Most importantly, in this fibrotic environment, both fibroblasts and 
myofibroblasts secrete increased amounts of ECM components to synthesise 
and maintain the ECM. The ECM is a complex and versatile network of cross-
linked and fibrous proteins that form a protective structure under healthy 
conditions; however, the excessive deposition of the matrix in IPF is thought 
to exert powerful effects on cell functions via ECM-cell interactions (Clarke et 
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al., 2013). As such, secreted TGF-β1 was shown to be a potent inducer of 
ECM production (Broekelmann et al., 1991), whereas the mechanical stress 
of ECM and contractile myofibroblasts further stimulate the activation of TGF-
β1 (Wipff et al., 2007). Fibroblasts are also capable of matrix degradation by 
producing MMPs and the tissue inhibitors of metalloproteinases (TIMPs) 
(Figure 2). However, the highly complex nature of ECM biology is reflected 
by the diverse roles of MMPs and TIMPs in fibrosis where they demonstrate 
both pro- and anti-fibrotic activities during the tissue remodelling phase 
(Giannandrea and Parks, 2014). Interestingly, the expression of several ECM-
degrading enzymes were shown to be elevated in the IPF lungs, however the 
excessive deposition of ECM components results in the accumulation and the 
development of a stiff matrix and ultimately lung fibrosis (Pardo et al., 2008; 
Kulkarni et al., 2016).  
 
Figure 2. Pulmonary fibroblasts interact with the extracellular matrix to 
enhance the fibrotic response. During the fibrotic response, the alveolar 
epithelial cells undergo apoptosis due to injury which results in the infiltration 
of fibroblasts and myofibroblasts into the alveolar space. The dysregulation of 
fibroblasts is thought to be a critical player in the development of IPF where 















matrix is maintained by the presence of pro-fibrotic mediators released by the 
fibroblasts and other cells. The interactions of the fibroblasts and the ECM 
further enhance the fibrotic response in a positive-feedback loop.  
 
1.2.5. TGF-β1 signalling 
TGF-β1 is one of the three isoforms of the TGF-β superfamily of growth factors 
which exerts its fibrotic effects by binding to the transmembrane TGF-β1 
(TβRI) and TGF-β2 (TβRII) receptors to initiate its signalling cascade. Briefly,  
signalling begins when secreted TGF-β1 binds to latent TGF binding proteins 
(LTBPs) and latency associated proteins (LAP) to form a large latent complex 
(LLC) which acts as a reservoir of inactive latent TGF-β1 in the ECM (Annes 
et al., 2003). TGF-β1 may be ‘activated’ and bind to its receptors only when it 
is liberated from the LLC complex by protease-mediated cleavage (Mu et al., 
2002) or by integrin-mediated interactions (Xu et al., 2009). Binding of TGF-
β1 to the TβRs leads to the formation of ligand-receptor heterotetrametric 
complexes and the phosphorylation of the cytoplasmic TβRI GS domain which 
initiates intracellular signalling via its interaction and phosphorylation of 
Smad2/Smad3 (R-Smads) (Shi and Massagué, 2003). The phosphorylation 
of Smad2/Smad3 leads to their partnering with the signalling transducer 
Smad4 and ultimately their translocation to the nucleus where they form 
transcriptional complexes to regulate gene expression (Zi et al., 2012). The 
Smad family of transcriptional activators form the canonical pathway of TGF-
β1 signalling, however several non-canonical TGF-β1 signalling pathways 
that complement Smad action have been identified to play a role in fibrosis 
(Figure 3). TGF-β1 has been shown to activate the Erk / mitogen-activated 
protein kinase (MAPK) pathway to mediate myofibroblast differentiation 
(Caraci et al., 2008) as well as collagen and connective tissue growth factor 
expression (Pannu et al., 2007). Additionally, TGF-β1-mediated p38 MAPK 
signalling has been shown to play a role in ECM production (Furukawa et al., 
2003). The  c-Jun N-terminal kinase (JNK) / MAPK signalling may also be 
activated by TGF-β1 to induce fibronectin synthesis  (Hocevar et al., 1999). 
TGF-β may also regulate the fibrotic response via the activation of the 
phosphatidylinositol-3-kinase (PI3K) / Akt  (Wilkes et al., 2005; Conte et al., 
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Figure 3. Activation of the Smad signalling pathway by TGF-β1 in 
pulmonary fibrosis. Latent TGF-β1 interacts with latency associated 
proteins (LAP) to form the large latent complex (LLC) which acts as a reservoir 
before the release of active TGF-β1. Upon activation of the TβR receptors by 
TGF-β1, the Smad intracellular signalling cascade is initiated (canonical 
pathway) which promotes the transcription of pro-fibrotic genes. Other 
signalling pathways (non-canonical pathways) such as MAPK and PI3K/Akt 
may also be activated by TGF-β1. P = phosphorylation.  
 
1.2.6. PDGF signalling 
The PDGF family of growth factors has been known to regulate cell growth 
and proliferation as potent mitogens of mesenchymal cells including 
myofibroblasts that play a crucial role in the development of fibrotic diseases 
(Bonner, 2004; Noskovičová et al., 2015). PDGF is primarily produced by 
platelets, vascular endothelial cells, alveolar macrophages and epithelial cells 
in human lungs. The PDGF family consists of the four polypeptide chains 
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PDGF-A, PDGF-B, PDGF-C and PDGF-D which form the biologically active 
homodimers including PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD as 
well the heterodimer PDGF-AB via a disulphide-bond linkage. PDGF-A and 
PDGF-B isoforms (-AA, -BB, -AB) are known to play important roles in fibrosis 
by binding to the PDGFR-α and -β receptors (Donovan et al., 2013), however 
much less is known about the activity of PDGF-C and PDGF-D isoforms 
(Beyer and Distler, 2013; Ying et al., 2017). Ligand-receptor binding leads to 
receptor dimerization and auto-phosphorylation which results in the 
phosphorylation of intracellular tyrosine kinase residues and the initiation of 
downstream signalling. PDGF-mediated signalling has been shown to 
activate the Ras-MAPK, phospholipase Cγ (PLCγ) signalling pathways to 
exert its mitotic effects (Andrae et al., 2008; Trojanowska, 2008) as well as 
the FAK (focal adhesion kinase) / PI3K / Akt (Reif et al., 2003) and signal 
transducer and activator of transcription 3 (STAT3) (Vij et al., 2008) signalling 
pathways to mediate the activity of fibroblasts (Figure 4).  
 
 
Figure 4. PDGF-A and PDGF-B isoforms are key players in PDGF 
signalling in pulmonary fibrosis. Activation of the PDGF receptors by 
PDGF isoforms leads to the transcription of genes involved in cell growth, 
proliferation and migration. Multiple intracellular signalling pathways have 
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been shown to be activated in pulmonary fibrosis by PDGF molecules such 
as JAK (Janus kinase) /STAT and PI3K/Akt pathways.  
 
1.2.7. IL-1β signalling 
IL-1β belongs to the IL-1 family of 11 cytokines and is primarily produced by 
monocytes, macrophages and dendritic cells, although B lymphocytes and 
Natural Killer (NK) cells are also known sources (Dinarello, 2009; Garlanda et 
al., 2013). IL-1β is a pro-inflammatory cytokine that is not normally expressed 
in healthy tissue, however it may be induced by the activation of the 
transcription factor, nuclear factor-κB (NF-κB) (Figure 5). The inactivate IL-1β 
pre-cursor is cleaved by caspase-1 to become active in response to 
inflammatory signals initiated by pathogens or other inflammatory cytokines. 
However, prior to cleavage of the IL-1β pre-cursor by caspase-1, a complex 
of intracellular proteins known as the inflammasome activate pro-caspase-1 
to the active caspase-1 (Latz et al., 2013). In most cells, caspase-1 is 
maintained in the inactive form in order to keep IL-1β activation highly 
regulated, however caspase-1 appears to be constitutively activated in human 
monocytes (Netea et al., 2009). An influx of calcium in the cell initiates the 
secretion of mature IL-1β which binds to the IL-1 receptors (IL-1R). Binding to 
the IL-1R1 initiates the downstream signalling cascade, however IL-1R 
accessory protein  and IL-1R2 appear to act as co-receptors  which interact 
with IL-1R1 to regulate its activity (Sims and Smith, 2010). The signalling 
cascade is initiated upon engagement of MyD88 (Myeloid differentiation factor 
88) adapter protein which is required for the activation of IRAK1 and IRAK2 
kinases through IRAK4. The IRAKs interact with E3 ubiquitin protein ligases 
such as TRAF6 (TNF receptor-associated factor 6) which ultimately leads to 
the recruitment of TAB2 and TAB3 which form the TAK1 (Transforming growth 
factor beta-activated kinase) kinase complex. TAK1 activates the IκΒ kinase 
(IKK) complex, also known as IKKγ, to induce activation of the NF-κB 
transcription factors (Cui et al., 2014; Gañán-Gómez et al., 2015). TAK1 was 
also shown to activate the MAPK signalling pathways p38α (Mitogen-




Figure 5. Activation of the NF-κΒ signalling pathway by IL-1β. Upon 
activation of the IL-1 receptors by IL-1β, the recruitment of adaptor proteins 
such as MyD88 initiate the activation of intracellular signalling pathways to 
activate transcription factors such as NF-κB. The activation of such signalling 
cascades ultimately results in the transcription of pro-inflammatory genes that 
have been shown to mediate cellular events in pulmonary fibrosis. P = 
phosphorylation. 
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1.2.8. Genetic studies in IPF 
IPF is a heterogeneous disease that is characterised by complex genetic and 
environmental interactions that contribute to the development of the disease; 
hence it is now thought that genetically susceptible individuals exposed to 
environmental stressor stimuli have an increased risk of developing the 
disease. Both rare and common genetic variants have been associated with 
sporadic and familial pulmonary fibrosis (Kaur et al., 2017).  
Genetic studies have linked IPF in adults to rare genetic variants in surfactant 
protein-related genes. Mutations have been found in the genes such as 
surfactant protein C (SFTPC) and A2 (SFTPA2) (Coghlan et al., 2014) which 
may result in alveolar epithelial cell injury following a disruption in their 
synthesis. Specifically, it appears that the SFTPC mutation causes defects in  
protein folding within the endoplasmic reticulum (ER) of type II AECs, which 
was associated with IPF progression (Lawson et al., 2008). Similarly, the 
SFTPA2 mutation was shown to enhance ER stress and has been associated 
with the development of pulmonary fibrosis (Maitra et al., 2010; Spagnolo and 
Cottin, 2017).  
Rare variants in several genes regulating telomere biology have also been 
identified in IPF patients, particularly mutations affecting telomerase and 
telomerase-associated proteins such as TERT  (Armanios et al., 2007; 
Coghlan et al., 2014) and TERC (Tsakiri et al., 2007). Telomeres are found at 
the end of chromosomes and protect them from DNA damage during the 
replication process. TERT and TERC encode telomerase genes which restore 
telomere length and mutations lead to increased telomere shortening. 
Interestingly, IPF has been associated with telomere shortening (Alder et al., 
2008), although the exact mechanisms that links this to the fibrotic response  
are still unclear.  
The single-nucleotide polymorphism rs35705950, located in the putative 
promoter region of the MUC5B gene was also found to play a role in 
predisposing patients to familial and sporadic forms of IPF by causing 
increased MUC5B expression (Seibold et al., 2011). The MUC5B gene 
encodes for mucin 5B, a gel-forming protein, expressed by epithelial cells.  
 25 
However, upregulated MUC5B expression is also observed in IPF patients in 
the absence of rs35705950 indicating alternative mechanisms that may 
increase MUC5B expression which are currently being investigated (Steele 
and Schwartz, 2013).   
1.2.9. Gene expression studies in IPF 
Transcriptional changes in the lungs of IPF patients have also contributed to 
our understanding of the disease and its underlying molecular mechanisms. 
In particular, microarray and sequencing based approaches have identified 
an  association between IPF and ECM formation, smooth muscle markers, 
growth factors, chemokines and immunoglobulins (Vukmirovic and Kaminski, 
2018).  
 
Several gene expression profiling studies have demonstrated widespread 
changes in the profile of mRNA (messenger RNA) expression in lung biopsies. 
A study by Nance et al.  identified 873 differentially expressed genes in IPF 
lung biopsies compared to controls using RNA-sequencing (RNA-seq). 
Interestingly, 675 of these genes displayed alternative splicing events 
including those coding for periostin (POSTN) and collagen (COL6A3) (Nance 
et al., 2014). Microarrays showed differential expression of 2940 genes in IPF 
lung tissue compared to controls, including genes encoding for collagens, 
proteinases, cytokines and growth factors (DePianto et al., 2015). The gene 
expression profile of control and IPF lung biopsies was also assessed using 
microarrays by Bridges et al. (Bridges et al., 2009). The Twist1 gene was the 
most consistently up-regulated in IPF lungs and was found to have a 
protective role against apoptosis. Gene expression was also assessed in the 
lungs of IPF patients to identify mechanisms of acute exacerbations. This 
study identified 579 differentially expressed genes including CCNA2 and α-
defensins which were amongst the most up-regulated genes (Konishi et al., 
2009). In another study, comparison of lung biopsies from relatively stable and 
progressive IPF patients, demonstrated differential expression of 243 
transcripts including CCL2 and SFTPA1 (Boon et al., 2009).  
As well as biopsies, gene expression in isolated human lung fibroblasts has 
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also been employed to examine and identify novel IPF-related genes and 
pathways. A recent study by Lee et al. identified CCL8 expression to be 
elevated in IPF lung fibroblasts using microarrays (Lee et al., 2017). Another 
report by Plantier et al. used publicly available microarray data to analyse and 
compare the expression of genes in cultured control and IPF fibroblasts 
(Plantier et al., 2016). Notably, two of the most significantly expressed factors 
were the connective tissue growth factor (CTGF) and serum response factor 
(SRF) which were shown to be overexpressed in IPF fibroblasts. Gene 
expression of lung fibroblasts was also assessed by microarrays following 4 
hour treatment with TGF-β1 (Renzoni et al., 2004). The expression of 129 
transcripts was shown to be driven by TGF-β1 stimulation including SMAD 
specific E3 ubiquitin protein ligase 2 (SMURF2), bone morphogenetic protein 
4, and angiotensin II receptor type 1 (AGTR1).  
In an attempt to identify circulating biomarkers of IPF, transcriptome analysis 
has also been undertaken on blood serum and plasma. A study by Yang et al. 
used microarrays to evaluate circulating genes in IPF patients based on 
disease severity. The study identified 1428 differentially expressed transcripts 
in the peripheral blood of mild IPF and 2790 differentially expressed 
transcripts in severe IPF compared to control patients. The genes encoding 
for MMP9 and IL-1R2 were found to be upregulated in both mild and severe 
IPF patients (Yang et al., 2012). Elevated levels of systemic MMP3 and 
CXCL13 were also identified in the blood of IPF patients using microarrays 
(DePianto et al., 2015).  
 
1.2.10. Current pharmacological strategies for the 
treatment of IPF 
There are currently two drugs that have been approved for the treatment of 
IPF, nintedanib and pirfenidone, both of which slow the decline of lung 
function associated with the disease. 
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Nintedanib, also known as BIBF1120, was originally developed as an anti-
cancer agent and is thought to be a non-specific tyrosine kinase inhibitor. A 
study by Hilberg et al. showed intracellular inhibition of the receptors for 
vascular endothelial growth factor (VEGFR), fibroblast growth factor (FGFR) 
and platelet-derived growth factor (PDGFR) by nintedanib (Hilberg et al., 
2008). Evidence that nintedanib has anti-fibrotic activities came from reports 
showing attenuated fibrosis in the bleomycin-induced model of lung fibrosis 
and inhibition of TGF-β-induced fibroblast to myofibroblast differentiation in 
vitro (Chaudhary et al., 2007; Wollin et al., 2014). It was also shown to inhibit 
collagen deposition induced by TGF-β in human lung fibroblasts in vitro 
(Hostettler et al., 2014). Nintedanib might also have anti-inflammatory activity 
following the observation that it reduced IL-1β production and lymphocyte 
counts in bronchoalveolar lavage fluid (BALF) obtained from human fibrotic 
lungs (Wollin et al., 2014). In 2014 nintedanib was approved by the US Food 
and Drug Administration (FDA) for oral use in IPF patients after the completion 
of the INPULSIS-1 and IMPULSIS-2 trials (Richeldi et al., 2014). The 
IMPULSIS trials were two 52-week parallel phase III randomised, double-blind 
trials to evaluate its safety and efficacy in a total of 1066 patients. Overall, 
nintedanib was shown to reduce the decline of FVC and was considered safe, 
with no significant increase in mortality rates compared to the placebo group. 
Mild to moderate diarrhoea was reported to be the most frequent adverse 
effect experienced by patients along with other events such as nausea and 
vomiting. 
 
Pirfenidone is thought to be an anti-oxidant and anti-inflammatory compound 
which was first shown to have anti-fibrotic activities in the bleomycin model of 
lung fibrosis (Spagnolo et al., 2015b). It was suggested to exert an anti-fibrotic 
effect by targeting and inhibiting TGF-β expression (Iyer et al., 1999). 
Pirfenidone was administered to terminally ill IPF patients for the first time in 
a clinical setting as part of a small open-label phase II study by Raghu et al. 
which showed promising results with satisfactory tolerability and relatively 
minor adverse events (Raghu et al., 1999). Pirfenidone has been shown to 
reduce levels of monocyte chemoattractant protein (MCP) -1, TGF-β, IFN-γ, 
FGF, IL-6,  IL-1β and other cytokines in the bleomycin-fibrosis model (Oku et 
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al., 2008). Human lung fibroblast proliferation and TGF-β-induced 
differentiation is also inhibited by pirfenidone in vitro.  Phosphorylation of 
Smad3, p38, and Akt, which are key molecules in the TGF pathway, were also 
decreased by pirfenidone (Conte et al., 2014), although its exact mechanism 
of action is still unclear. Pirfenidone was approved as the first anti-fibrotic 
therapy for IPF following the demonstration of improved mortality and reduced 
disease progression during the CAPACITY (Noble et al., 2011)  and  ASCEND 
trials (King et al., 2014). The CAPACITY trials (studies 004 and 006) 
evaluated the oral administration of pirfenidone for at least 72 weeks. 
Paradoxically, although one trial (004) showed an overall reduction in the 
decline of FVC, this was not observed in the other trial (006) (Noble et al., 
2011). This led to the ASCEND trial which evaluated the administration of 
pirfenidone in 555 patients over 52 weeks. In this trial, pirfenidone was shown 
to slow the decline in lung function, improve exercise tolerance and to be 
generally safe and well tolerated with an acceptable adverse event profile 




















1.3. Non-coding RNAs 
 
Initial data from the Human Genome Project indicated that there were 
approximately 30,000 to 40,000 protein coding genes in the human genome 
(Lander et al., 2001). However, this estimate was significantly reduced to 
20,000 to 25,000 in the final draft published three years later (International 
Human Genome Sequencing Consortium, 2004). In terms of the total length 
of the human genome (approximately 3 billion), this meant that just 1-2% 
codes for the exonic regions of proteins. Although the function of the 
remaining DNA is currently an area of investigation, we know that much of this 
is transcribed into RNA  which is not translated and is therefore classified as 
‘non-coding RNA’ (ncRNA) (Kaikkonen et al., 2011; Morris et al., 2014). 
Despite being initially considered as ‘junk’, ncRNAs are now known to have 
multiple biological functions and play a significant role in health and disease 
(Esteller et al., 2011; Kopp and Mendell, 2018).  
 
The term ncRNA includes all RNA molecules that do not encode for proteins, 
a very big proportion of these are the well-known ‘housekeeping’ RNAs 
including transfer RNAs and ribosomal RNAs, which play a critical role in 
protein biosynthesis. In addition, there are the small nucleolar RNA (snoRNA), 
which regulate the transcriptional modification of other RNA species and the 
small nuclear RNAs (snRNA), that form an important component of the 
spliceosome complex, which removes introns from mRNA during 
transcription. In total, these ‘housekeeping RNAs” represent around 85-90% 
of the total RNA whilst the mRNAs account for 5-8%. The  remaining ncRNAs 
are speculated to have regulatory roles in various cellular functions and are 
divided in two classes, the short (< 200 nucleotides) which are exemplified by 
the microRNA (miRNA) and long (> 200 nucleotides) non-coding RNAs 
(lncRNAs) (Kaikkonen et al., 2011). miRNAs are thought to predominantly 
regulate gene expression at the translational level and lncRNAs at the 
transcriptional level (Figure 6). 
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Regulatory ncRNAs are now believed to regulate multiple biological 
responses whilst their aberrant expression has been linked to pathologic 
conditions. This introduction will provide an overview of lncRNAs and their role 















Figure 6. LncRNAs are novel modulators of transcription. LncRNA 
transcripts are thought to interfere with the expression of protein coding genes 
at the transcriptional level, whereas miRNAs are thought to silence the 


















1.3.1. Long non-coding RNAs 
LncRNAs are defined as endogenous cellular RNA molecules of more than 
200 nucleotides in length, that lack an open reading frame (ORF) of significant 
length (less than 100 amino acids) and contain 2 or more exons (Mendell et 
al., 2004; Gutschner and Diederichs, 2012). They were originally discovered 
in mice via large-scale sequencing of full-length cDNA libraries during the 
FANTOM project (Okazaki et al., 2002), and since then it has become clear 
that mammalian genomes encode numerous lncRNAs. 
Currently there are 15,779 lncRNA genes and 28,468 lncRNA transcripts 
documented in the human genome database (version 28) of GENCODE 
(genome database), compared to 19,901 protein coding genes (Gencode, 
2018). The total number of lncRNAs continues to increase due to the 
development of advanced deep sequencing technologies which contribute to 
the discovery of novel lncRNA genes, some of which were previously 
mistakenly identified as protein coding genes (Pertea and Salzberg, 2010). 
Interestingly, a study by Djebali et al. identified protein-coding transcripts to 
accumulate primarily in the cytosol, whereas lncRNAs are more enriched in 
the nucleus (Djebali et al., 2012). 
As with protein-coding genes, the majority of lncRNAs appear to be 
transcribed by RNA polymerase II (RNAPII) (Guttman et al., 2009). There are 
a few exceptions that are transcribed by RNA polymerase III (RNAPIII) 
including the short interspersed element (SINE) B2 RNA which was found to 
repress RNAPII transcription (Allen et al., 2004). As with mRNAs, lncRNAs 
have also been found to be subjected to transcriptional editing such as 
splicing, polyadenylation and 5’ capping (Guttman et al., 2009). Subsequently, 
each lncRNA develops a final stable structure which shapes its unique cellular 
function and enables it to interact with other molecules (Blythe et al., 2016).  
Despite the rapid increase in data relating to lncRNAs, little is known regarding 
their exact functions, mechanism of action or even how many different types 
of lncRNAs exist. Even though these transcripts are generally poorly 
evolutionary conserved (Necsulea et al., 2014), it is now evident that they play 
an important role in multiple biological pathways including the modulation of 
 32 
developmental processes and pathophysiological states (Esteller et al., 2011; 
Chen et al., 2017b). 
1.3.2. LncRNA classification 
A convenient way to classify lncRNAs is based upon their position relative to 
well-established markers such as protein-coding genes (Figure 7). However, 
several lncRNAs do not fit into any of these categories as they present a 
combination of these qualities or they cover long genomic distances (Kung et 
al., 2013). The most significant lncRNA classes will be discussed below.  
 
1.3.2.1. Antisense lncRNAs 
Antisense lncRNAs, also known as natural antisense transcripts or NATs, are 
transcribed across the exons of protein-coding genes from the opposite 
strand, with varying degrees of overlap from partial to complete. Gene 
regulation by antisense transcripts occurs mainly in cis (Magistri et al., 2012), 
where the antisense lncRNA interacts with its associated or neighbouring 
genes. GENCODE currently lists 5,501 antisense lncRNA genes and 11,161 
transcripts (Gencode, 2018). Interestingly, it is suggested that as much as 
70% of protein coding genes have antisense counterparts (Faghihi and 
Wahlestedt, 2009; Villegas and Zaphiropoulos, 2015). 
 
1.3.2.2. Long intergenic non-coding RNAs 
Long intergenic non-coding RNAs (lincRNAs) are considered the largest and 
most significant group of lncRNAs, constituting approximately half the overall 
number of lncRNAs. GENCODE currently lists 7,490 lincRNA genes giving 
rise to 13,598 lincRNA transcripts (Gencode, 2018). They are stand-alone 
transcripts that are located between protein coding genes and can regulate 
gene expression by acting either in cis or in trans. Prior to the advent of 
sequencing, lincRNAs were originally identified using two markers of active 
transcription: trimethylation of lysine 4 of histone H3 (H3K4me3) and 
trimethylation of lysine 36 of histone H3 (H3K36me3), present at their 
promoter during RNAPII transcription (Guttman et al., 2009).  LincRNAs 
appear to have undergone rapid evolution and show variable conservation 
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across species (Ransohoff et al., 2018). In a study by Ulitsky et al. mammalian 
lincRNA orthologues were found for just 5.1% of  zebrafish lincRNA genes, 
demonstrating poor overall conservation when compared to protein coding 
genes (Ulitsky et al., 2011). Cabili et al. characterised the expression of 
human lincRNAs across 24 cell types and tissues using RNA-seq. LincRNAs 
were found to have lower expression levels, fewer exons and to be expressed 
in a cell-specific manner compared to mRNAs. LincRNA loci were typically 
found on average within 40kb of protein coding genes (Cabili et al., 2011). 
Interestingly, some of the best characterised and well-studied lincRNAs such 
as XIST (X inactive specific transcript) and HOTAIR (HOX transcript antisense 
RNA) have been shown to be important epigenetic regulators. These 
chromatin-associated lincRNAs were shown to mediate protein coding gene 
expression by recruiting and directing chromatin-modifying complexes to 
specific DNA regions leading to epigenetic modifications (Ulitsky and Bartel, 
2013).  
 
1.3.2.3. Enhancer RNAs 
Enhancer RNA (eRNA) transcripts are found in both polyadenylated or non-
polyadenylated forms and are reported to be bi-directionally expressed at 
active enhancer regions of the genome (Natoli and Andrau, 2012). Enhancers 
are DNA areas located near protein coding genes which contribute to the 
initiation of transcription by promoting the binding of transcription factors and 
other co-factors. Notably, a study by Kim et al. (Kim et al., 2010) revealed 
RNAPII-mediated transcription of eRNAs from enhancer regions in the 
presence of histone H3 monomethylated at lysine 4 (H3K4me1) which 
correlated with the activity of mRNA synthesis. As such, eRNAs are mainly 
thought to be cis-acting lncRNAs which control promoter and enhancer 
interactions as well as chromatin structures; resulting in the regulation of gene 
expression by promoting transcription of neighbouring genes (Chen et al., 
2017a; Liu, 2017). Hence, eRNAs synthesis and enhancer activity are thought 
to be strongly correlated in regulating the transcriptional activity of 
neighbouring genes.  
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1.3.2.4. Intronic RNAs 
Intronic lncRNAs are entirely transcribed from the introns of annotated protein 
coding genes in either a sense or antisense direction. These lncRNAs have 
been associated with the nesting of small ncRNAs such as miRNAs and 
snoRNAs as well as circular non-coding RNAs (circRNAs) (Zhang et al., 
2013).  In a study by Ayupe et al. intronic RNAs showed evidence of RNAP-
II-mediated transcription and 5’-cap modifications (Ayupe et al., 2015). The 
functions of intronic lncRNAs remain largely unclear as they are a relatively 
unexplored class of lncRNAs and further investigation into their mechanisms 
of regulation is necessary. However, it has been suggested that intronic 
lncRNAs are often co-transcribed with their host protein coding gene, thus 
possibly sharing strong regulatory features and relationships with their host 
gene (Boivin et al., 2018).  
Figure 7. Classification of the most widely found lncRNAs according to 
their genomic location. Attempts to resolve the transcriptomic complexity of 
lncRNAs have led to their classification based on their genomic proximity to 
protein coding genes. LincRNAs and eRNAs are stand-alone transcription 
units situated near protein coding genes. Intronic lncRNAs are found within 
the introns of protein coding genes, while antisense lncRNAs are transcribed 



















circRNAs are a class of recently discovered regulatory RNAs which were 
found to interact and regulate the activity of miRNAs, hence usually referred 
to as ‘miRNA sponges’ (Ebert et al., 2007; Hansen et al., 2011). A study by 
Memczak et al.  identified approximately 2,000 human, 1,900 mouse and 700 
nematode circRNAs that may be expressed from both coding and non-coding 
genomic loci (Memczak et al., 2013). circRNAs have been found to localise 
primarily in the cytoplasm and  inhibit miRNAs by acting as miRNA-competing 
transcripts (Jeck et al., 2013; Hansen et al., 2013). Interestingly, another type 
of circRNAs, known as circular intronic RNAs (ciRNAs) were shown to be 
located in the nucleus acting as cis-regulators of RNAPII-mediated 
transcription and expression of parent genes  (Zhang et al., 2013). 
 
1.3.2.6. Pseudogenes 
The non-coding genome also gives rise to pseudogenes which are derived 
from protein coding genes that lose their coding potential through evolution 
(Balakirev and Ayala, 2003). There are currently 14,723 pseudogenes 
annotated in GENCODE (version28). However, it appears that a number of 
pseudogenes may potentially regulate the expression of protein coding genes  
by processing into short interfering RNAs or acting as miRNA decoys 
(sponges) to regulate oncogenes during cancer progression (Pink et al., 
2011). Pseudogenes were also reported to be co-transcribed with their parent 
gene, function as antisense transcripts or even produce short peptides (Li et 




1.3.3. Characteristics of lncRNAs 
LncRNAs present several distinct characteristics when compared to mRNAs 
regarding their size, specificity, organisation and subcellular localisation. 
However, despite the differences, they also possess a lot of similarities to 
mRNAs regarding their biogenesis and form.  
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1.3.3.1. LncRNAs and mRNAs share similar biogenesis 
pathways 
LncRNAs are predominantly transcribed by RNAPII and most are spliced, 
polyadenylated at the 3’-end, 5’-end capped with 7-methylguanosine and are 
associated with similar histone  markers  to those of mRNAs (Guttman et al., 
2009; Hon et al., 2017; Derrien et al., 2012). Non-polyadenylated lncRNAs, 
including those associated with enhancer regions (Natoli and Andrau, 2012), 
are thought to be stabilised through other mechanisms. These include 
ribonuclease P (RNase P) cleavage to generate mature 3’-ends, the formation 
of circular molecular structures such as circRNAs or capping by small 
nucleolar ribonucleoproteins (snoRNP) complexes (Memczak et al., 2013; 
Zhang et al., 2014b). Unlike mRNAs which are known for their protein coding 
functions and translational potential, lncRNAs lack an ORF of significant 
length and quality (Derrien et al., 2012) and are therefore deemed to have no 
translational capacity. However, interestingly a study by Ruiz-Orera et al. 
suggested that lncRNAs may give rise to small novel peptides (Ruiz-Orera et 
al., 2014). 
 
1.3.3.2. LncRNAs are expressed at lower levels compared 
to mRNAs 
LncRNAs are generally shorter in length, have fewer but longer exons and are 
expressed at lower levels compared to mRNAs (Cabili et al., 2011; Derrien et 
al., 2012; Hezroni et al., 2015). Indeed, lncRNAs demonstrated lower 
expression in all tissues compared to mRNAs except in the testes where they 
showed tissue-specific elevated expression levels (Cabili et al., 2011; Melé et 
al., 2017; Necsulea et al., 2014; Ransohoff et al., 2018). These lower 
expression levels were initially advanced as evidence that lncRNAs were 
simply the result of transcriptional ‘noise’. This has since been disproved 
following evidence showing biological functionality (see Section 1.3.4).  
 
1.3.3.3. LncRNAs expression is cell and tissue specific 
Transcriptome-wide studies demonstrated that expression of lncRNAs is 
specific for the cell, tissue, developmental or disease state, as well as highly 
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dependent on context and time (Derrien et al., 2012; Ulitsky and Bartel, 2013; 
Melé et al., 2017; Cabili et al., 2011). For example, Cabili et al. found that 78% 
of lincRNAs were tissue-specific across 24 tissue and cell types compared to 
approximately 19% of protein coding genes (Cabili et al., 2011). This 
specificity of lncRNA expression may explain their low levels of expression 
compared to mRNAs and indicates that they possess cell/tissue selective  
functions (Gloss and Dinger, 2016).  
 
1.3.3.4. LncRNAs show poor evolutionary conservation  
Unlike protein coding genes, lncRNAs generally show poor evolutionary 
conservation (Derrien et al., 2012; Cabili et al., 2011; Necsulea et al., 2014) 
and this lack of sequence conservation has made it difficult to identify 
functional domains and to compare their biological significance across 
species (Rands et al., 2014). In general, the exon regions of lincRNAs were 
shown to demonstrate higher conservation than random un-transcribed 
intragenic regions although still considerably less than that observed in exon 
regions of protein coding genes. Interestingly, the conservation across the 
promoter regions of lncRNAs is comparable to that of protein coding genes 
(Guttman et al., 2009; 2010). This lack of conservation appears to be related 
to the rapid evolution of lincRNAs, most lincRNAs have no conserved 
orthologues (Hezroni et al., 2015). In contrast to sequence conservation, 
thousands of lncRNAs were found to demonstrate highly conserved genomic 
positions (synteny) (Ulitsky et al., 2011). Despite the general observation of 
poor conservation, a small number of lncRNAs demonstrate high conservation 
at both sequence and structure level and include well-characterised lincRNAs 
such as MALAT1 (metastasis associated lung adenocarcinoma transcript 1) 
and NEAT1 (nuclear enriched abundant transcript 1) (Johnsson et al., 2014).  
 
1.3.3.5. Subcellular localisation of lncRNAs 
After transcription in the nucleus, mRNA transcripts tend to be transported to 
the cytoplasm where they undergo translation. In contrast, lncRNAs are found 
both in the nucleus and the cytoplasm although current evidence suggests 
that are predominantly enriched in the former (Derrien et al., 2012; Djebali et 
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al., 2012). Nuclear lncRNAs include some of the best studied lncRNAs such 
as NEAT1 (Clemson et al., 2009), MALAT1 (Tripathi et al., 2010) and XIST 
(Brown et al., 1992) where they are thought to regulate epigenetic 
modifications and mRNA processing. However, even though lncRNAs as a 
group are more enriched in the nucleus compared to mRNAs, cytoplasmic  
lncRNAs are reported to be expressed in higher numbers (Ulitsky and Bartel, 
2013; Rashid et al., 2016). Interestingly, a report by van Heesch et al. (van 
Heesch et al., 2014) showed a 30% enrichment of lncRNAs in the cytoplasm 
and 38% in ribosomal fractions compared to just 17% in the nucleus. 
Additionally, ribosome-profiling experiments have found abundant numbers of 
lncRNAs associated with ribosomes, suggesting they may actually be 
translated (Ingolia et al., 2011; Ruiz-Orera et al., 2014). However, further 
studies failed to detect protein products from the supposed translation of 
lncRNA ORFs, suggesting that ribosomes can distinguish between coding 
and non-coding transcripts and concluding that lncRNAs are unlikely to 
encode peptides/proteins (Quinn and Chang, 2016).  
 
1.3.4. Biological significance of lncRNAs  
LncRNAs are a relatively novel class of RNA molecules, hence their functions 
remain largely unexplored. They were originally considered transcriptional 
‘noise’ and although the majority are still likely to be biologically inactive there 
is emerging evidence that a substantial number have functional activity. In 
particular, a number of highly expressed lncRNAs such as HOTAIR (Gupta et 
al., 2010), XIST (Brown et al., 1992; Cerase et al., 2015), MALAT1 (Tripathi 
et al., 2010), and H19 (Raveh et al., 2015) have been studied in more depth 
and are relatively well-characterised. Nuclear located lncRNAs are generally 
associated with chromatin modifications, transcriptional regulation and RNA 
processing, whereas cytoplasmic lncRNAs have been linked with mRNA 
stability/translation and as direct agonists/antagonists of protein expression 
(Figure 8). As such, lncRNA transcripts have been associated with the 
regulation of all aspects of mRNA processing and protein activity (Zhang et 




Figure 8. Biological functions of lncRNAs. LncRNAs were shown to 
interact with protein coding genes and their transcripts to regulate gene 
expression. (A) Nuclear lncRNAs interact with chromatin remodelling factors 
and transcription factors to regulate the expression of neighbouring or distal 
genes. (B) Nuclear lncRNAs also regulate transcription and several other 
transcriptional events of RNA processing. (C) Cytoplasmic lncRNAs were 
shown to interfere with post-transcriptional regulation such as mRNA stability 
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1.3.4.1. Chromatin modifications 
LncRNAs have been implicated in the regulation of epigenetic changes 
through recruiting and guiding chromatin remodelling complexes to specific 
genomic loci both in cis and in trans to regulate transcription (Figure 9). The 
chromatin remodelling complexes may exert their effects by repressing or 
activating the expression of protein coding genes via the recruitment of 
chromatin-modifying factors such as the Polycomb repressive complexes 
(PRC1 and PRC2) and histone methyltransferases (Saxena and Carninci, 
2011; Han and Chang, 2015). 
 
For example, one of the first lncRNAs to be characterised was the mammalian 
cis-acting XIST which mediates the silencing of one X chromosome in females 
during development. XIST induces the formation of repressive chromatin and 
the recruitment of PRC proteins (PRC2) to completely inactivate one of the 
two X chromosomes by dosage compensation during the early embryonic 
development of females. Interestingly, other lncRNAs have been shown to 
interact with and regulate the expression of XIST, with the most prominent 
being its own natural antisense lncRNA (TSIX) (Pontier and Gribnau, 2011; 
Froberg et al., 2013; Lee and Bartolomei, 2013). Another well-studied lncRNA 
is HOTTIP (HOXA Distal Transcript Antisense RNA) which was found to 
promote the expression of the HOXA gene. HOTTIP directly interacts with 
adaptor protein WDR5 and the mixed-lineage leukaemia protein 1 (MLL1) 
histone lysine methyltransferase complex (also known as Histone-lysine N-
methyltransferase 2A) to recruit them to the HOXA locus through chromatin 
looping, causing H3K4 trimethylation and inducing the transcription of HOXA 
(Wang et al., 2011).  
 
LncRNAs can also migrate from their site of transcription and regulate the 
expression of genes in trans either distally located on the same chromosomes 
or on different chromosomes. Such a lncRNA is the well-studied antisense 
intergenic lncRNA HOTAIR which is transcribed from the HOXC locus (Gupta 
et al., 2010). HOTAIR is thought to silence the transcription of the distant 
HOXD gene by acting as a scaffold for the recruitment of the repressive 
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chromatin PRC2 complex leading to H3K27 trimethylation and H3K4 
demethylation (Kugel and Goodrich, 2012; Hajjari and Salavaty, 2015). 
 
LncRNAs have also been associated with the regulation of the monoallelic 
expression (only one of the two copies of a gene is expressed) of genes 
according to their parents of origin, also known as genomic imprinting. 
Imprinted control regions may be associated with the expression of lncRNAs, 
such as the paternally expressed Airn lncRNA, also known as  IGF2R-AS1, 
which was shown to silence the maternally expressed genes 
Igf2r/Slc22a2/Slc22a3 (Sleutels et al., 2002). The imprinted lncRNA clusters 
are thought to silence the expression of neighbouring genes in cis by 
recruiting chromatin-modifying complexes and maintaining repressive DNA 
methylation at adjacent loci (Kanduri, 2016).  
 
 
Figure 9. LncRNAs function in cis and in trans to regulate gene 
expression. LncRNAs interact with chromatin remodelling factors and 
binding proteins in order to regulate the expression of (A) neighbouring genes, 
in cis or (B) in trans, distally located genes that could be located on the same 
or a different chromosome.  
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1.3.4.2. Transcriptional regulation 
The process of transcription and the associated RNA processing and 
organisation of the nuclear architecture, may also be regulated by lncRNA 
transcripts. LncRNAs have been shown to regulate transcription factors and 
the RNAP-II transcription machinery, leading to an increase or suppression of 
transcription, as well as mRNA processing mechanisms including  splicing, 
capping and editing (Geisler and Coller, 2013). For example, the lncRNA 
MALAT1 is found in nuclear speckles and is thought to regulate alternative 
splicing of mRNAs (Tripathi et al., 2010). MALAT1 may act as a scaffold by 
guiding serine/arginine (SR) splicing factors to sites of transcription where 
splicing takes place (Kopp and Mendell, 2018). Another example is the natural 
antisense transcript ZEB2 (NAT) which was shown to regulate the expression 
of the Zeb2 gene via splicing of an internal ribosome entry site (IRES) located 
within an intron in the 5-untranslated region (UTR) of the Zeb2 gene (Beltran 
et al., 2008).  
 
1.3.4.3. Post-transcriptional regulation 
Several lncRNAs are transported from the nucleus to the cytoplasm where 
they are thought to be involved in regulating mRNA stability and translation. 
As an example, the ubiquitin carboxy-terminal hydrolase L1 antisense RNA 1 
(Uchl1-as1) exhibits positive regulation of translation of the Uchl1 protein 
through the embedded inverted SINEB2 element, although its exact 
mechanism of action is unclear  (Carrieri et al., 2012; Podbevšek et al., 2018). 
In contrast, the lincRNA-p21 (also known as tumour protein p53 pathway core- 
pressor 1) was shown to inhibit the translation of target mRNAs  by negatively 
regulating the translation of CTNNB1 (β-catenin) and JUNB (transcription 
factor jun-b) (Yoon et al., 2012). LncRNAs such as 1/2-sbsRNAs and gadd7 
have also been shown to regulate mRNA stability through interactions with 
various proteins including Staufen1 (STAU1) and cyclin-dependent kinase 6 
(Cdk6), respectively (Gong and Maquat, 2011). Additionally, lncRNAs such as 
the natural antisense BACE1-AS and TINCR were shown to enhance mRNA 
stability in vitro (Zhang et al., 2014a; Rashid et al., 2016). Interestingly, 
lncRNAs may also regulate mRNA expression by binding to specific miRNAs 
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where they function as competing endogenous RNAs (ceRNAs). ceRNAs 
were shown to protect target mRNAs from repression by acting as ‘miRNA 
sponges’, presenting another post-transcriptional regulatory role of lncRNAs 
(Cesana et al., 2011; Salmena et al., 2011; Zhang et al., 2014a).  
 
1.3.5. LncRNAs and the regulation of lung fibrosis 
Our knowledge of the role of lncRNAs in IPF is currently very limited. A 
microarray study by Cao et al. using the bleomycin-induced lung fibrosis rat 
model identified differential expression levels of multiple lncRNAs and 
mRNAs, most significantly lncRNAs AJ005396 and S69206 (Cao et al., 2013). 
A subsequent study using the bleomycin model focused on two differentially 
expressed lncRNAs, MRAK088388 and MRAK081523 and reported that 
these could regulate expression of protein coding genes by acting as ceRNAs 
(sponges) for miR-29b-3p and let-7i-5p (Song et al., 2014). In a similar vein, 
Huang et al. identified 34 lncRNAs with potential miRNA binding sites 
suggesting possible lncRNA-miRNA interactions. Real-time polymerase chain 
reaction (RT-PCR) confirmed the expression of these lncRNAs in human IPF 
lung tissue and 9 of them were dysregulated in IPF.  Knockdown of lncRNAs 
CD99P1 and n341773 indicated that these might regulate lung fibroblast 
differentiation and proliferation (Huang et al., 2015). More recently, 
sequencing and microarray analysis of mouse fibrotic lungs identified 513 up-
regulated and 204 down-regulated lncRNAs, of which uc.77 and 
2700086A05Rik were found to mediate changes in EMT when overexpressed 
(Sun et al., 2016). Wu et al. has demonstrated that silica-induced pulmonary 
fibrosis may be inhibited by miR-489 in mice. miR-489 was also shown to 
suppress fibroblast differentiation and inflammation by targeting Smad3 and 
MyD88, respectively. Interestingly, the upregulation of the lncRNA CHRF 
(cardiac hypertrophy-related factor) was found to reverse the inhibitory effects 
of miR-489 in mice, as well as in macrophage and fibroblast cell lines. This 
suggests that CHRF may play a role in the regulation of miR-489 and the 
activation of the inflammation and fibrotic signalling pathways (Wu et al., 
2016). The expression of lncRNA H19 has also been implicated in the 
development of pulmonary fibrosis in a study by Tang et al. (Tang et al., 2016). 
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LncRNA H19 was found to interact with miR-29b and to exert pro-fibrotic 
effects by regulating the expression of collagen and α-smooth muscle actin in 
the bleomycin model of fibrosis. However, another study demonstrated 
upregulated expression of lncRNA H19 in the bleomycin mouse model as well 
as in fibroblast cell lines following TGF-β1 exposure (Lu et al., 2018). LncRNA 
H19 was found to act as a ceRNA for miR-196a to regulate collagen 
expression. Moreover, the elevated expression of lncRNA AP003419.16 in 
the peripheral blood of IPF patients has been linked with the increased risk of 
developing age-associated IPF (Hao et al., 2017). Interestingly, the 
expression of lncRNA NONMMUT065582, also known as pulmonary fibrosis-
associated RNA (PFAR), was found to be elevated in the fibrotic lungs of mice 
as well as mouse fibroblasts (Zhao et al., 2018). LncRNA PFAR was shown 
to promote the development of fibrosis by acting as ceRNA for miR-138 and 
regulating the expression of yes-associated protein 1 (YAP1).  
 
Table 1. LncRNAs associated with pulmonary fibrosis 
LncRNA Effect on fibrosis Research model Reference 
AJ005396, 
S69206 
Pro-fibrotic Bleomycin-induced fibrosis 
rat model 
(Cao et al., 2013) 
MRAK088388, 
MRAK081523 
Pro-fibrotic Bleomycin-induced fibrosis 
rat model 








Pro-fibrotic  Paraquat-induced fibrosis 
mouse model 
(Sun et al., 2016) 
lncRNA CHRF Pro-fibrotic Silica-induced fibrosis 
mouse model 
(Wu et al., 2016) 
LncRNA H19 Pro-fibrotic Bleomycin-induced fibrosis 
mouse model 
(Tang et al., 
2016) 
LncRNA H19 Pro-fibrotic Bleomycin-induced fibrosis 
mouse model, human 
fibroblast cell line MRC-5 
(Lu et al., 2018) 
AP003419.16 Pro-fibrotic Human blood samples (Hao et al., 2017) 
PFAR Pro-fibrotic Bleomycin-induced fibrosis 
mouse model, primary 
mouse fibroblasts 




1.3.6. LncRNAs in other types of fibrosis 
As with IPF, the role of lncRNAs in the development of other types of fibrosis 
including that observed in the heart, liver and kidney is currently under 
investigation. 
 
In cardiac fibrosis, the cardio-protective lncRNA, myosin heavy chain-
associated RNA transcript (Mhrt) was found to bind to the helicase domain of 
the chromatin-remodelling factor BRM/SWI2-related gene 1 (Brg1) and 
thereby prevent DNA binding. Through inhibiting the action of Brg1, this 
lncRNA was shown to protect the heart from fibrosis and remodelling (Han et 
al., 2014). As observed in the lung, CHRF has also been associated with the 
regulation of cardiac hypertrophy by targeting miR-489 and regulating MyD88 
expression (Wang et al., 2014). In addition, the circulating lncRNA LIPCAR 
(long intergenic non-coding RNA predicting cardiac remodelling) has been 
proposed as a novel biomarker of cardiac remodelling (Kumarswamy et al., 
2014). Expression of lncRNA-H19 was found to be up-regulated in cardiac 
fibroblasts and fibrotic tissues and to play a role in proliferation and fibrosis, 
potentially through the regulation of DUSP5 (Dual specificity protein 
phosphatase 5) (Tao et al., 2016). More recently, knockdown of a lncRNA 
named myocardial infarction associated transcript (MIAT) was shown to 
attenuate fibrosis by decreasing collagen production and proliferation in 
cardiac fibroblasts. Mechanistic studies showed that MIAT acted as a ceRNA 
(sponge) for the miR-24 (Qu et al., 2017).  
 
In the case of hepatic fibrosis, the maternally expressed gene 3 (MEG3) may 
possess an important role in fibrosis as it was found to be downregulated in 
the  CCL4–induced liver fibrosis model and human fibrotic liver tissues (He et 
al., 2014). Although its role in hepatic fibrosis is still unclear, exposure of 
human hepatic stellate cell lines (HSC) LX-2 cells to TGF-β1 resulted in 
decreased expression of MEG3 and an increase in α-SMA expression. More 
importantly, methylation of the MEG3 promoter and subsequent expression of 
MEG3 were found to be regulated by DNA methyltransferase 1 (DNMT1), 
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while the depletion of DNMT1 was shown to affect α-SMA and COL1A1 
mRNA and protein expression in TGF-β1-treated hepatic stellate LX-2 cells 
(He et al., 2014). LincRNA-21 demonstrated reduced expression in mice 
hepatic fibrosis models and was shown to regulate primary HSC activation by 
promoting p21 (cyclin-dependent kinase inhibitor 1) expression, leading to 
inhibition of the cell cycle and proliferation in vitro (Zheng et al., 2015). Another 
study by Yu et al. demonstrated elevated expression of lncRNA APTR (Alu-
mediated p21 transcriptional regulator) in hepatic fibrotic tissues and TGF-β1 
activated HSC. Knockdown of APTR was shown to inhibit fibrosis in vivo and 
activation of HSC, as well as increase the expression of p21 and inhibit cell 
cycle progression and proliferation (Yu et al., 2015a). LncRNA growth arrest-
specific transcript 5 (GAS5) was also found to play a role in hepatic 
fibrogenesis with reduced expression in mouse, rat, human fibrotic liver tissue 
and in activated HSCs. GAS5 was shown to be primarily located in the 
cytoplasm, acting as a ceRNA for miR-222 and reducing the activation and 
proliferation of HSCs (Yu et al., 2015b). 
 
The role of lncRNAs in renal fibrosis also remains largely unexplored. A recent 
study by Xie et al. showed that lncRNA-H19 expression is upregulated in renal 
fibrosis in both TGF-β2-induced HK-2 cell fibrosis in vitro and during unilateral 
ureteral obstruction (UUO)-induced renal fibrosis in vivo. LncRNA-H19 
knockdown was shown to attenuate fibrosis via interactions with miR-17 and 
fibronectin, suggesting that inhibition of LncRNA-H19 may potentially present 
a novel anti-fibrotic treatment (Xie et al., 2016). In a different study, RNA 
sequencing identified 151 lncRNAs associated with the TGF/Smad3 signalling 
pathway using the UUO-induced mouse model of renal fibrosis (Zhou et al., 
2014). Arvaniti et al. identified numerous genes that were differentially 
expressed in the UUO renal fibrosis mouse model including several lncRNAs; 
the functional roles of RP23-45G16.5, 3110045C21Rik and AI662270 
lncRNAs were also investigated. Overexpression of RP23-45G16.5 in mouse 
kidney epithelial cells (M-1 cell line) was shown to upregulate CCL2 mRNA 
levels while 3110045C21Rik overexpression was found to elevate CDH1 (e-
cadherin) and inhibit α-SMA and TGFB1 mRNA expression. AI662270 
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lncRNA failed to demonstrate any significant effect on expression of these 
genes  (Arvaniti et al., 2016).  
 
1.3.7. miRNAs 
LncRNAs may also give rise to miRNAs which can either be embedded within 
their exons or intron regions; thus many are named after the lncRNA host 
gene from which they are encoded (Dykes and Emanueli, 2017).  
 
miRNAs are commonly evolutionarily conserved and are the most well studied 
class of ncRNAs. They are 20-25 nucleotide long single–stranded molecules 
that are thought to modulate gene expression at the post-transcriptional level 
via the RNA interference pathway (O’Reilly, 2016). Primary miRNAs are 
transcribed in the nucleus by RNAP-II and these capped and polyadenylated 
transcripts are then processed by Drosha, a RNAse III ribonuclease, into 
precursor miRNAs. They are then transported from the nucleus into the 
cytoplasm by exportin 5 through the nuclear pore complexes for further 
processing by DICER, a second RNAse III endonuclase, to give rise to mature 
double stranded miRNAs. The mature miRNA is incorporated into the RNA–
induced silencing complex (RISC) where the mature miRNA strand (guide 
strand) binds to a member of the Argonaute (ago) protein family complex that 
mediates gene silencing by either repression of mRNA translation or reduction 
in mRNA stability, following binding within the 3’ untranslated region (3’UTR) 
of target mRNAs. The other strand (passenger stand) is usually degraded, 
however in rare cases it remains functional (Jiang et al., 2010; Vettori et al., 
2012). Since their initial discovery in Caenorhabditis elegans in 1993 (Lee et 
al., 1993), miRNAs have received remarkable research interest and it is now 
evident that they play a crucial role in the regulation of multiple cellular 
processes and their aberrant expression is implicated in various human 
diseases (Li and Kowdley, 2012). miRNAs have been associated and shown 
to interfere with several crucial cellular processes such as proliferation, 
differentiation and apoptosis (Carleton et al., 2007). 
 
Many miRNAs are now associated with the development and progression of 
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fibrosis with evidence suggesting that they directly regulate multiple molecules 
within the pro-fibrotic pathways including TGF signalling, collagen deposition 
or ECM synthesis. As such, miRNAs are considered an attractive therapeutic 
target using locked nucleic acid (LNA) antisense technology to antagonise 
their function (Jiang et al., 2010; O’Reilly, 2016). Several antagomirs such as 
anti-miR-26a (Liang et al., 2014a) and let-7d (Pandit et al., 2010) have been 
used to block the functions of various miRNAs associated with fibrosis both in 
vivo and in vitro. However, only the anti- miRNA-122 oligonucleotide is 
currently in clinical use for the treatment of hepatitis C infection, marketed as 
Miravirsen (Janssen et al., 2013). 
1.3.7.1. miRNAs and their role in IPF 
IPF may also be linked to changes in the expression of miRNAs, with a report 
showing that approximately 10% of miRNAs are differentially expressed in IPF 
patients (Pandit et al., 2011). miRNAs have been proposed to mediate 
pulmonary fibrotic processes by acting either as positive or negative entities 
exerting pro-fibrotic or anti-fibrotic effects respectively. 
There are numerous miRNAs associated with the development of IPF, 
however miRNAs such as miR-29, miR-26α, miR-21 and Let-7d have 
attracted significantly more interest and their mechanism of action is better 
understood. Overexpression of miRNAs such as miR-199a-5p and miR-21 
were shown to promote myofibroblast differentiation induced by TGF-β1 in 
lung fibroblasts (Lino Cardenas et al., 2013; Liu et al., 2010). Upregulation of 
miR-145 is also seen in IPF lungs and following TGF-β1 activation in human 
lung fibroblasts (Yang et al., 2013). Several other miRNAs were also shown 
to promote fibrosis such miR-424, miR-210, miR-96 and miR-154; leading to 
TGF-β1-induced EMT in lung epithelial cells (miR-424), increasing hypoxia-
induced lung fibroblast proliferation (miR-210), enhancing the proliferative and 
anti-apoptotic phenotype in IPF fibroblasts (miR-96) and stimulating the 
proliferation and migration of lung fibroblasts (miR-154) (Xiao et al., 2015; 
Bodempudi et al., 2014; Nho et al., 2014; Milosevic et al., 2012).  
Interestingly, anti-fibrotic miRNAs appear down-regulated in IPF lungs 
including the miR-29 family, which was shown to be further suppressed upon 
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TGF-β1 exposure in human fibroblasts (Cushing et al., 2011). A study by Xiao 
et al. suggests that miR-29 is a downstream target gene of Smad3 and 
negatively regulated by TGF-β/Smad signalling in pulmonary fibrosis (Xiao et 
al., 2012). miR-29 has also been shown to inhibit the expression of ECM 
components in fibroblasts grown on IPF-derived ECM (Parker et al., 2014). 
miR-26α and let-7d are also down-regulated in pulmonary fibrosis and are 
further suppressed by TGF-β1 in a Smad3-dependent manner (Pandit et al., 
2010; Liang et al., 2014a). miR-26α  and let-7d may mediate EMT in IPF via 
the transcriptional factor HMGA2 (Pandit et al., 2010; Liang et al., 2014b). 
miR-326 is another miRNA thought to impact upon the lung fibrotic response 
via regulation of the TGF-β1 signalling pathway and several other pro-fibrotic 
genes (Das et al., 2014).  
1.4. Conclusion  
It has become evident that our understanding of the complex mechanisms 
that regulate gene expression are still at an early stage. In particular, the 
advent of high-throughput sequencing technologies has revolutionised our 
ability to examine the genome and transcriptome under physiological and 
pathological conditions. One of the newest families of regulatory elements to 
be identified are the long non-coding RNAs, with emerging evidence that 
these regulate multiple biological responses and that changes in their 
expression may be related to the development of disease. Indeed, there is 
now evidence that lncRNAs are dysregulated in several types of cancer, in 
the immune response as well as neurological disorders (Schmitt and Chang, 
2016; Clark and Blackshaw, 2014; Chen et al., 2017c).  
 
IPF is a fatal progressive chronic disease characterised by scar tissue 
accumulation in the lungs leading to impaired gas exchange and restricted 
ventilation. Previous studies have identified several miRNAs that may play an 
important role in the development of fibrosis. In contrast, little is known about 
the role of lncRNAs in the pathogenesis of IPF and it is this question that was 





Although IPF is a complex disease with an unknown aetiology, several key 
cells including lung epithelial cells and fibroblasts have been implicated in the 
initiation and progression of the disease. We hypothesise that “lncRNAs 
regulate the function of human fibroblasts in the normal and IPF lungs”.  
To examine this hypothesis, we addressed the following aims and compiled 
the resulting data into three publications:  
 
1. Identified lncRNAs that were differentially expressed between normal 
and IPF lung biopsies (Chapter 2) 
2. Identified lncRNAs that were differentially expressed between normal 
and IPF lung fibroblasts (LINC00960 and LINC01140) (Chapter 2) 
3. Identified lncRNAs that were differentially expressed following TGF-β1-
induced activation of control and IPF lung fibroblasts (Chapter 2) 
4. Examined whether differences between control and IPF lung 
fibroblasts are reflected at the epigenetic level using a histone marker 
of primed promoters and enhancers, H3K4me1 (Chapter 2) 
5. Compared the TGF-β1-induced fibrotic response, PDGF-ΑΒ-induced 
proliferative response and the IL-1β-induced inflammatory response 
between control and IPF lung fibroblasts (Chapter 2) 
6. Examined the role of the differentially expressed long non-coding 
RNAs (LINC00960 and LINC01140) in the TGF-β1-induced fibrotic 
response, PDGF-ΑΒ-induced proliferative response and the IL-1β-
induced inflammatory response in control and IPF lung fibroblasts 
(Chapter 2) 
7. Identified lncRNAs that were differentially expressed following IL-1β-
induced activation of control lung fibroblasts (IL7AS and MIR3142HG) 
(Chapter 3) 
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8. Examined the role of the differentially expressed lncRNAs (IL7AS and 
MIR3142HG) in the IL-1β-induced inflammatory response in control 
and IPF lung fibroblasts (Chapter 3) 
9. Examined the effect of pirfenidone and nintedanib on the TGF-β1, 
PDGF-AB and IL-1β-induced responses of control and IPF lung 



















2. Chapter 2 –   
Long intergenic non-coding RNAs 
regulate human lung fibroblast 
function: Implications for 
idiopathic pulmonary fibrosis 
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Phenotypic changes in lung fibroblasts are believed to contribute to the 
development of Idiopathic Pulmonary Fibrosis (IPF), a progressive and fatal 
lung disease.  Long intergenic non-coding RNAs (lincRNAs) have been 
identified as novel regulators of gene expression and protein activity. In non-
stimulated cells, we observed reduced proliferation and inflammation but no 
difference in the fibrotic response of IPF fibroblasts. These functional changes 
in non-stimulated cells were associated with differential expression of 
H3K4me1, a histone marker of primed promoters and enhancers. Following 
activation with TGF-β1 and IL-1β, we demonstrated an increased fibrotic but 
reduced inflammatory response in IPF fibroblasts. There was no significant 
difference in proliferation following PDGF exposure. The lincRNAs, 
LINC00960 and LINC01140 were upregulated in IPF fibroblasts. Knockdown 
studies showed that LINC00960 and LINC01140 were positive regulators of 
proliferation in both control and IPF fibroblasts but had no effect upon the 
fibrotic response. Knockdown of LINC01140 but not LINC00960 increased the 
inflammatory response, which was greater in IPF compared to control 
fibroblasts. Overall, these studies demonstrate for the first time that lincRNAs 
are important regulators of proliferation and inflammation in human lung 
fibroblasts and that these might mediate the reduced inflammatory response 
observed in IPF-derived fibroblasts.  
 
2.2. Introduction 
Idiopathic pulmonary fibrosis (IPF) is a fatal progressive chronic disease 
characterised by scar tissue accumulation in the lungs leading to impaired gas 
exchange and restricted ventilation 1-3. The etiology and pathogenesis of the 
disease are still unclear, although recent research has indicated that 
persistent epithelial injury and/or exposure to pathogens, leads to the 
secretion of fibrotic, proliferative and inflammatory mediators such as TGF-β1 
4, PDGF 5 and IL-1β 6 . These are then thought to act upon surrounding 
fibroblasts, to induce an exaggerated wound healing response that 
contributes towards the development and progression of IPF 1,3.  
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Comparison of the phenotype of lung fibroblasts derived from IPF patients 
with those from non-fibrotic patients has shown that these exhibit multiple 
differences including reduced apoptosis 7,8 and diminished capacity to 
synthesis cyclooxygenase 2 and prostaglandin E2 9. Differences have also 
been observed in proliferation and release of fibrotic components, although 
these have resulted in contradictory observations 10-13. Attempts to 
understand these persistent phenotypic changes at the epigenetic level have 
shown differences in the pattern of DNA methylation 14,15. However, although 
there are reports of histone changes associated with individual genes linked 
to IPF 16, there has been no attempt to determine if there are genome wide 
changes in the profile of histone modifications. 
 
High-throughput sequencing indicates that much of the human genome is 
transcribed into non-coding RNAs (ncRNAs). The majority of ncRNAs (>90%) 
are involved in house-keeping activities such as translation (ribosomal RNA), 
splicing (short nuclear RNAs) and post-transcriptional RNA modifications 
(short nucleolar RNA) whilst the others are broadly classified as either short 
ncRNAs (<200 nt (nucleotides)) or long ncRNAs (lncRNAs) (>200 nt). The 
microRNA family of short ncRNAs are the best characterised and are known 
to induce mRNA degradation or block messenger RNA (mRNA) translation 
via the RNA interference pathway 17. In contrast, little is known about lncRNAs 
which are commonly divided into three groups: long intergenic non-coding 
RNAs (lincRNAs) that are located between protein-coding genes, antisense 
that are transcribed across protein coding genes on the reverse strand and 
pseudogenes, that are non-translated versions of protein coding genes 18,19. 
In most cases, it is believed that the actions of lncRNAs are mediated through 
domains that interact with proteins, acting as scaffolds or to modulate their 
activity 20,21. At the present time, a number of miRNAs have been implicated 
in the regulation of fibroblast function and in the development of IPF including 
let-7d 22, miR-17~92 23, miR-101 24 and miR-155 25. In contrast, although there 
is accumulating evidence to indicate that lncRNAs are important regulators of 
biological response 18,19, little is known regarding the role of lncRNAs in lung 
fibroblast function or IPF.  
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In this report, we have demonstrated differences in the functional responses 
between fibroblasts derived from control and IPF lungs. These are reflected 
by changes in H3K4me1, a histone epigenetic marker of primed genes and 
enhancers 26,27 and up-regulation of two lincRNAs, LINC00960 and 
LINC01140 in IPF fibroblasts. Functional analysis has shown that the both 
LINC00960 and LIN01140 are required for proliferation and that LINC01140 
is a negative regulator of the inflammatory response. Given that LINC01140 
is upregulated in both IPF fibroblasts and lung biopsies, our data suggest that 





Source and fibroblast cell culture  
Control (age = 50 ± 3y; 3 male and 2 females) and IPF fibroblasts (age = 62 
± 1y; 3 male and 2 females) were obtained from Professor Carol Ferghali-
Bostwick (Medical University of South Carolina, USA) and the Coriell Institute 
of Medical Research (Camden, New Jersey, USA). Approval was obtained 
from the Medical Board of the Medical University of South Carolina and the 
Coriell Institute of Medical Research with patients proving material with 
informed consent. All methods were performed in accordance with the 
relevant guidelines and regulations. Neither the control or IPF patients had a 
history of smoking. Isolation of lung fibroblasts was initiated using explants of 
minced lung tissue. Fibroblasts were cultured in DMEM (high glucose, 
pyruvate) growth media (11995-073, ThermoFisher) supplemented with 10% 
(v/v) FBS (Fetal Bovine Serum) (11550356, ThermoFisher), 1% (v/v) 
Penicillin-Streptomycin (11548876, ThermoFisher) and 0.1% (v/v) Fungizone 
(15290-018, ThermoFisher). All cultures were maintained in a 37oC, 5% (v/v) 
CO2 humidified incubator. Upon reaching approximately 80-90% confluency 
cells were washed in sterile 1x PBS (Phosphate Buffered Saline) (P5493, 
Sigma-Aldrich) followed by treatment with StemPro® Accutase® cell 
detachment solution (11599686, ThermoFisher). All experiments were 
performed using cells plated at passage 6 to 7.  
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Plating and treatment of fibroblasts for pharmacological studies  
1 x 104 cells were plated in 96 cell culture wells on day 1 and allowed to adhere 
overnight. On day 2, cells were serum-deprived by reducing FBS to 0.1% in 
200μl of starvation media. Fibroblasts were then treated with the required 
concentration of TGF-β1 (recombinant human, expressed in Chinese hamster 
ovary cell line, R&D systems, 240-B-002/CF) and IL-1β (recombinant, 
expressed in E. coli, Sigma-Aldrich, I9401-5UG) and incubated for the 
indicated time before supernatants were collected for protein quantification 
assessment. 
 
Preparation and treatment of fibroblasts used in microarray analysis  
5 x 105 cells of control and IPF lung fibroblasts were seeded in 25 cm2 cell 
culture flasks (Nunc EasyFlasks, Thermo Fisher Scientific) and medium was 
replaced until the cells reach near-confluency state. Their growth medium was 
then replaced with 3ml starvation medium (0.1% FBS) and left overnight. The 
following day, the cells were treated with and without 3 ng/ml TGF-β1 for 24 
hours (hrs) before all supernatants were collected and cells were lysed.  
 
Cell Proliferation 
Lung fibroblast proliferation was evaluated by measuring cell viability with the 
Cell Counting Kit-8 (CCK-8, Sigma-Aldrich). Cells (5000) were seeded in a 
96-well plate and incubated overnight in 100 μl growth media (10% FBS). The 
following day, the cells were serum-deprived and treated with the indicated 
concentration of PDGF-ΑΒ (recombinant human, E. coli derived, R&D 
systems, 222-AB-010) and then incubated for the indicated times. Before the 
end of each assay, 10 μl of the CCK-8 solution was added into a final volume 
of 100 μl cultured media and incubated for 2 hrs before absorbance was 
measured using a microplate reader (Fluostar Optima, BMG Labtech). The 
absorbance wavelength was measured at 450 nm and 600 nm which was then 
subtracted during data analysis.  
 
Transfection with LNA antisense 
On the day of transfection, 5 µL of HiPerFect (Qiagen) was mixed with 200 µL 
of growth media without antibiotics, serum or antifungals to prepare the 
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transfection mix. LNA GapmeRs were added to 200 µL of the transfection mix 
at a final concentration of 30 nM, placed in 12-well plates and incubated for 
minimum 10 mins at room temperature. Fibroblasts were then seeded at a 
density of 5x105 cells per well in 200 µL of growth media and incubated with 
the transfection mixes at 37oC, 5% (v/v) CO2 overnight. The next day, 800 µL 
of media (0.1% FBS) was added to the wells to dilute out the lipid-LNA 
complexes and reduce the toxicity of the reaction. The cells were stimulated 
with either 3 ng/ml of TGF-β1 or 3 ng/ml of IL-1β and incubated for 24 hrs 
before harvesting for RNA extraction and ELISA (Enzyme-linked 
immunosorbent assay) analysis. The same transfection protocol was followed 
for the cell viability assays (CCK-8 kit) with or without 100 ng/ml of PDGF-AB 
stimulation for 72 hrs, however 96 well plates were used and the reaction 
volume and reagents were reduced accordingly. LNA GapmeR sequences: 
Negative Control LNA1 - TCATACTATATGACAG; Negative Control LNA2 - 
GACGGTAAGTAGGCGA; LINC00960 LNA1 – GGCGTGAGAGTAAAGC; 
LINC00960 LNA2 – GTGCTTAGGCTTAGAG; LINC01140 LNA1 – 
TTTAATTGGGCCGTCT; LINC01140 LNA2 – TTGACACGGCTGACTT. 
 
Measurement of IL-6 and PAI-1 release 
Supernatants of cultured lung fibroblasts were collected and used to assess 
secretion of IL-6 and PAI-1, using the DuoSet ELISA (DY206 and DY1786) 
Development System Kits (R&D Systems Europe, UK) following the 
manufacturer’s instructions. Samples and standard curve samples were 
diluted as appropriate in reagent diluent. Absorbance was measured at 
450nm with wavelength correction at 570nm using a microplate reader 
(Fluostar Optima, BMG Labtech). 
 
RNA isolation and quality control 
For all samples, total RNA was extracted using the RNeasy kit (Qiagen), 
included an on-column DNase treatment (Qiagen), according to the 
manufacturer’s guideline. RNA concentration was determined using the Qubit 
2.0 (Life Technologies). RNA quality was measured using the Agilent 
Bioanalyzer and produced RIN values of >8.0. 
 
 60 
Quantitative PCR validation of lncRNA expression  
For quantitative PCR (qPCR), cDNA libraries were prepared from total RNA 
using the High capacity cDNA RT kit (Applied Biosystems, Life Technologies, 
4368813). Expression of mRNAs and lncRNAs were determined by qPCR 
using the SYBR® Green PCR mix (Applied Biosystems; primers were 
obtained from Sigma-Aldrich and are listed in Supplementary Table 1). For 
analysis, the 2−(ΔΔCt) method was used to determine relative-quantities of 
individual mRNAs and lncRNAs which were normalized to 18S ribosomal 
RNA. qRT-PCR primer sequences: 18S – AAACGGCTACCACATCCAAG 
(Forward), CCTCCAATGGATCCTCGTTA (Reverse); IL-6 – 
ACTCACCTCTTCAGAACGAATG (Forward), 
CCATCTTTGGAAGGTTCAGGTTG (Reverse); LINC00960 – 
TCCAGGCGTCATAACCAACC (Forward), CGGTGCTTAGGCTTAGAGGG 
(Reverse); LINC01140 – CATCTCATCGGCATGGACCT (Forward), 
CAAACTGGACTGACTTTCACCA (Reverse). 
 
Transcriptome analysis of microarray data 
The Affymetrix GeneChip™ Command Console Software was used to 
summarise probe intensity data and to generate a CEL file for each sample. 
The CEL files were then processed by the Affymetrix Expression Console™ 
using Robust Multi-chip Analysis (RMA) to generate CHP files (Probe-level 
summarisation) following the manufacturers manual. The CHP files were then 
used for Quality Control analysis which generated a full report with the array 
QC metrics and appropriate algorithm parameters. Using the data of the CHP 
files, a 3-dimensional Principle Component Analysis (PCA) graph was 
generated accounting for the majority of variance based on a set of variables 
PCA1, PCA2 and PCA3 in the original data set. CHP files generated by the 
Expression Console Software were used in the Transcriptome Analysis 
Console (TAC) Software to perform statistical analysis and obtain a list of 
differentially expressed genes. To run the TAC software, a library folder 
containing the annotation files was required (HTA-
2_0.na36.hg19.probeset.csv) and installed. CHP files were imported and 
separated into different condition groups for analysis using the Gene Level 
Differential Expression Analysis tool. A master table was generated containing 
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signal expression levels of all 67528 transcript clusters (genes) covered in the 
arrays, 44699 protein coding and 22829 non-protein coding. Signal intensity 
for each transcript cluster was presented as a Bi-weight average signal (log2) 
value and depending on which two conditions were compared the values of 
ANOVA p-value, FDR p-value (based on Benjamini-Hochberg Step-Up FDR-
controlling Procedure) and gene fold change were adjusted accordingly. 
 
Transcriptome analysis of sequencing data from lung biopsy samples 
Previously reported sequencing data obtained from the biospies of 19 control 
and 20 IPF lungs (GSE92592) 50 were downloaded from Sequence Read 
Archive (SRA) (https://www.ncbi.nlm.nih.gov/sra) using the following 
command in SRA tools: fastq-dump -I --split-files <file_name>. The paired end 
reads were aligned to the human reference genome (hg38) using Hisat2 
(version 2.0.4) 51,52 using the following command line options: hisat2 -q --dta 
--rna-strandness FR –x <reference-genone.gtf> -1 <forward_strand.fa> -2 
<reverse-strand file.fa> –S <output.sam>. Output SAM files were then sorted 
and converted to BAM files (samtools sort -@ 8 –o output.bam output.sam) 
and indexed (samtools index –b output.bam) in Samtools 53. The profile of 
gene expression (using the Gencode v27 database) in the BAM files for each 
samples were determined using Stringtie 54: stringtie <sample.BAM> -G 
<GenCodev26.gtf> -o <samples.gtf> -e -A <sample.txt>. Following feature 
counting: featureCounts -a <reference-genome.gtf> -g gene_name -o 
counts.txt Control_*.bam IPF_*.bam the differential gene expression was 
assessed using DeSeq2 and the following R script: curl -s -O 
http://data.biostarhandbook.com/rnaseq/code/deseq2.r  cat simple_counts.txt 
| Rscript deseq2.r 19x20 > results_deseq2.txt. 
 
Chromatin immunoprecipitation, sequencing and analysis of H3K4me1  
Chromatin immunoprecipitation (ChIP) using a H3K4me1 antibody 
(Diagenode, C15410037) and the iDeal ChIP-seq kit for Histones kit 
(Diagenode, C01010051) was performed on the 5 control and 5 IPF fibroblast 
samples. In addition, we performed ChIP on a single control and IPF using an 
IgG antibody to provide a background control. Paired-end 75bp sequencing 
data were obtained using the Illumina HiSeq4000 at the Oxford Genomics 
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Centre at the Wellcome Centre for Human Genetics (funded by Wellcome 
Trust grant reference 203141/Z/16/Z). FASTQ sequencing data from control 
(n=5) and IPF (n=5) fibroblasts was aligned to hg38 using Bowtie 2 55: bowtie2 
-q --very-fast <reference_genome.gtf>  -U <file_name.fastq> -S 
<output_file.sam>. Output SAM files were then sorted and converted to BAM 
files (samtools sort -@ 8 –o output.bam output.sam), indexed (samtools index 
–b output.bam) in Samtools 53 and then converted to BigWig format using 
BamCoverage (which is part of the deepTools suite 56) using the following 
command line: bamCoverage -b <input_bam.bam> --normalizeUsingRPKM -
-binSize 30 --smoothLength 300 -p 10 --extendReads 200 -o 
<output_file.bw>. Significant ChIPseq peaks (q = <0.1) in each sample were 
called with MACS2 57 using the broadpeak options: macs2 callpeak –t 
<sample> -c <backgrounf_igG> --broad - <output_files> -g hs. The differential 
expression of H3K4me1 peaks was determined by inputing the individual Bam 
files (Bowtie2) and BED files (Broadpeaks output - MACS2) for control and 
IPF samples into Diffbind (version 2.2.1) on Galaxy (at www.usegalaxy.org) 
58. Control 1 was omitted as an outlier following PCA analysis.  
Principle Component Analysis and Hierarchical Clustering 
The abundance of Gencode v27 defined genes in individual samples was 
defined as the fragments per kilobase exon per million reads mapped (FPKM) 
and determined using Stringtie (RNA). PCA and hierarchical clustering on 
Gencode v27 genes demonstrating an expression >1 FPKM was performed 
using Genesis (v1.7.7) 59. Data were log2 transformed following the addition 
of 1 FPKM. The threshold for reporting gene expression at FPKM >1 is based 
upon the ability to validate sequencing data using qRT-PCR. 
 
Data Access 
The microarray and ChIPSeq sequencing data is available from the gene 
expression omnibus under GSEXXXXX and GSEXXXXX. The RNA data for 
control and IPF biopsies is available GSE92592. 
 









Our initial aim was to determine whether there were significant differences in 
the phenotypic responses of lung fibroblasts derived from control lung and IPF 
patients. We selected high-throughput approaches to measure the time- and 
concentration dependency of their TGF-β1-induced fibrotic response, PDGF-
induced proliferation and IL-1β-stimulated inflammatory response. 
 
Comparison of the TGF-β1-stimulated PAI-1 release from 
control and IPF lung fibroblasts  
 
TGF-β1-induced activation of lung fibroblasts triggers the expression of PAI-
1 (also known as Serpin E1), a protein known as an important regulator of 
fibrinolysis and wound healing and therefore implicated in the process of 
fibrosis 28. To assess potential difference in the fibrotic response in control 
and IPF fibroblasts we examined the time- and concentration-dependent 
release of PAI-1 release in response to TGF-β1.  
 
Initial studies showed a time-dependent release of PAI-1 from non-stimulated 
IPF cells, which reached significance at 48 hrs and 72 hrs (Figure 1A/B). 
However, comparison between control (4.4 ± 2.2 ng/ml) and IPF (5.1 ± 1.4 
ng/ml) at 72 hrs showed no significant difference. Exposure to TGF-β1 
produced a comparable time dependent increase in PAI-1 release from 
control and IPF fibroblasts, that was significant at 24 hrs and continued to 
increase at 48 hrs and 72 hrs (Figure 1C/D). There was no significant 
difference between the control and IPF fibroblasts at 72 hrs with absolute 
values of 25.3 ± 2.0 ng/ml and 26.6 ± 5.3 ng/ml, respectively. 
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To examine the concentration-dependent response, cells were incubated for 
72 hrs with 0.01 to 10 ng/ml TGF-β1 and compared with time matched non-
stimulated cells. As expected, TGF-β1 induced a concentration-dependent 
increase in PAI-1 release in both control (Figure 1E) and IPF (Figure 1F) 
fibroblasts that plateaued at 21.6 ng/ml and 19.0 ng/ml, respectively. The 
baseline expression in non-stimulated control and IPF fibroblasts was 2.7 
ng/ml and 3.4 ng/ml. Comparison of the mean logEC50 between the control 
(pEC50 = 0.49 ± 0.05) and IPF (pEC50 = 0.85 ± 0.13) individuals showed a 
significant difference (p < 0.05; unpaired t-test). In relation to PAI-1 release, 
these studies show IPF fibroblasts are more fibrotic since they demonstrate 
increased sensitivity to TGF-β1 activation. 
 
Figure 1. IPF lung fibroblasts showed increased sensitivity to TGF-β1-
stimulated PAI-1 release. Time course of PAI-1 release from non-stimulated 
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(A/B) and TGF-β1-stimulated (C/D) fibroblasts derived from control (white) 
(A/C) and IPF (grey) (B/D) patients. PAI-1 release from control (E) and IPF 
(F) fibroblasts at 72 hrs following exposure to the indicated TGF-β1 
concentrations. Data represents the mean +/- SEM of five individuals. 
Statistical significance was performed using 1-way analysis of variance 
(ANOVA) with a Dunnett’s test for time courses (A-D) where * = p <0.05, ** = 
p <0.01, *** = p <0.001 and **** = p <0.0001. The logEC50 for each individual 
was determined in GraphPad Prism and comparison between control and IPF 
groups was performed using an unpaired t-test. The EC50 was calculated from 
the mean logEC50 values.  
 
Comparison of PDGF-AB-stimulated proliferation in control 
and IPF lung fibroblasts  
 
PDGF-AB is a potent mitogen that has been previously shown to stimulate the 
proliferation of lung fibroblasts 29. To assess the proliferative response in 
control and IPF fibroblasts, we investigated the time- and concentration-
dependent effect of PDGF-AB on the fibroblast cell number. Initial 
examination of the proliferation in non-stimulated fibroblasts showed 
increased proliferation in control versus IPF at 72 hrs (Figure 2A). On top of 
the baseline increases demonstrated in Figure 2A, exposure to 100 ng/ml 
PDGF-AB was demonstrated to induce an additional time dependent 
proliferation in both control and IPF fibroblasts, with an increase 1.8 fold and 
2.1 fold at 72 hrs, respectively (Figure 2B/C).  
 
Following exposure to recombinant human PDGF-AB (0.3 – 300 ng/ml), we 
observed a concentration-dependent increase in proliferation at 72 hrs, 
although we observed wide variation in the response of IPF fibroblasts (Figure 
2E) compared with controls (Figure 2D). Comparison of the mean logEC50 
values showed no significant difference between control and IPF fibroblasts. 
These results indicated that there was a significant increase in proliferation in 
non-stimulated control fibroblasts versus IPF, there was no difference in the 




Figure 2. Non-stimulated IPF lung fibroblasts show a reduced 
proliferative response. Proliferation in non-stimulated control (white) and 
IPF fibroblasts (grey) was measured 72 hrs using cell count (A). Time course 
of proliferation in PDGF-stimulated (from control (B) and IPF (C) patients). 
Proliferation in control (D) and IPF (E) fibroblasts at 72 hrs following exposure 
to the indicated PDGF concentrations. Data represents the mean +/- SEM of 
five individuals. Statistical significance was performed using 1-way analysis of 
variance (ANOVA) with a Dunnett’s test for time courses (A-C) where * = p 
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<0.05, ** = p <0.01 and **** = p <0.0001. The logEC50 for each individual was 
determined in GraphPad Prism and comparison between control and IPF 
groups was performed using an unpaired t-test. The EC50 was calculated from 
the mean logEC50 values.  
 
 
Comparison of IL-1β-stimulated IL-6 release in control and 
IPF lung fibroblasts  
 
The pro-inflammatory cytokine IL-1β has been shown to potently induce IL-6 
release from various cell types including fibroblasts 30,31. To assess potential 
differences in the inflammatory response, we examined the time- and 
concentration-dependent IL-1β induced IL-6 release from control and IPF lung 
fibroblasts. 
 
Interestingly, we observed a time dependent IL-6 release in non-stimulated 
fibroblasts, which was significantly increased in control (67.1 ± 19.8 pg/ml) 
versus IPF (3.7 ± 0.9 pg/ml) fibroblasts at 72 hrs (p = 0.018: unpaired t-test) 
(Figure 3A/B). Exposure to 3 ng/ml IL-1β induced a comparable time-
dependent release of IL-6 from control and IPF fibroblasts, which was initially 
detected at 4 hrs and continued to increase over the 72 hrs period, with a 
maximum of 723 ± 134 pg/ml and 483 ± 85 pg/ml, respectively (Figure 3C/D). 
There was no significant difference in the maximal values between control and 
IPF at 72 hrs (Figure 3C/D).  
 
To examine the concentration-dependency, cultured cells were incubated for 
72 hrs with increasing concentrations of IL-1β ranging from 0.03 to 30 ng/ml 
(Figure 3E/F). Comparison of the logEC50 values showed a significant 
reduction (p = 0.0234) between control (pEC50 = 0.99 ± 0.19) and IPF (pEC50 
= 0.25 ± 0.17) fibroblasts. Based upon IL-6 release, this data would indicate 
that IPF fibroblasts are less inflammatory than control cells as they 





Figure 3.  IPF lung fibroblasts show a reduced inflammatory response. 
Time course of IL-6 release from non-stimulated (A/B) and IL-1β-stimulated 
(C/D) fibroblasts derived from control (white) (A/C) and IPF (grey) (B/D) 
patients. IL-6 release from control (E) and IPF (F) fibroblasts at 72 hrs 
following exposure to the indicated IL-1β concentrations. Data represents the 
mean +/- SEM of five individuals. Statistical significance was performed using 
1-way analysis of variance (ANOVA) with a Dunnett’s test for time courses (A-
D) where * = p <0.05, ** = p <0.01, *** = p <0.001 and **** = p <0.0001. The 
logEC50 for each individual was determined in GraphPad Prism and 
comparison between control and IPF groups was performed using an 
unpaired t-test. The EC50 was calculated from the mean logEC50 values.  
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Phenotypic differences between control and IPF fibroblasts 
are reflected at the epigenetic level 
 
Having demonstrated differentially functional responses between control and 
IPF fibroblasts, we examined whether these differences were reflected at the 
epigenetic level. To this end we examined the histone modification H3K4me1, 
a marker that has previously been associated with primed promoter and 
enhancer regions 26,27. Comparison between non-stimulated control and IPF 
fibroblasts identified 462 regions of differential expression (Supplemental 
Table 1). As examples, we have included the profiles of the H3K4me1 peaks 
associated with CCL8 and MRAP (Figure 4A). Unsupervised hierarchical 
clustering showed a clear difference (separation) of the control and IPF 
samples (Figure 4B) indicating that the phenotypic differences are indeed 
reflected at the epigenetic level. Pathway analysis of the genes in which these 
regions overlapped or which were closest (Supplemental Table 1) showed 
that these were associated with tight junctions, cancer and inflammation 
(Figure 4C). Interestingly, these genes were also strongly associated with 
tobacco user disorder (1.4 x 10-13) despite no history of smoking in either the 







Figure 4. Differential expression of the H3K4me1 epigenetic mark 
between control and IPF fibroblasts. ChIP sequencing was employed to 
examine the differential expression of H3K4me1, a marker of primed promoter 
and enhancer regions. (A) examples of the H3K4me1 regions associated with 
CCL8 and MRAP, (B) unsupervised hierarchical clustering was calculated 
within the DiffBind programme and (C) pathways analysis of H3K4me1 
associated genes was undertaken using DAVID. 
 
 
Differential long non-coding RNA expression between control 
and IPF fibroblasts  
 
Having demonstrated differentially functional responses between control and 
IPF fibroblasts, we wondered whether these might be related to long non-
coding RNAs (lncRNAs). To this end, we compared the expression profile in 
control and IPF lung fibroblasts in non-stimulated cells and those exposed to 
3 ng/ml TGF-β1 for 24 hrs, using the Affymetrix GeneChip™ Human 
Transcriptome Arrays 2.0 (Supplemental Table 2). TGF-β1 exposure resulted 
in widespread and shared changes in gene expression in both control (1331 
genes including 10 lincRNAs and 14 antisense: Supplemental Table 3) and 



















































Supplemental Table 4) (Figure 5A), q <0.05. As might be expected, pathway 
analysis (DAVID Bioinformatics) showed that the highest hit for the up-
regulated genes were extracellular matrix (9.9 x 10-15). Amongst this group, 
PAI-1 (Serpin E1) gave one of the highest fold changes in both the control 
(44-fold) and IPF fibroblasts (31-fold). Comparison of the lists of genes that 
were changed following TGF-β1 exposure identified only 77 that were 
differentially expressed between control and IPF, which includes a single 
lincRNA (LOC100507516) whose expression was reduced in IPF 
(Supplemental Table 5).  
 
To identify those lncRNAs that might regulate the fibrotic, proliferative and 
inflammatory response, we compared the profile of gene expression in non-
stimulated fibroblasts. This identified differential expression of 104 genes 
including 2 lincRNAs (LINC00960 and LINC01140) that were increased in IPF 
(Supplemental Table 6), p <0.05. Interestingly, there was also a general down-
regulation of small nucleolar RNAs (snoRNAs), that are commonly associated 
with splicing, as well as changes in a number of inflammatory genes including 
CXCL8 down-regulation and CXCL11 up-regulation (Supplemental Table 6). 
In subsequent functional studies, we focused upon the role of the lincRNAs, 
LINC00960 and LINC01140. Initial qRT-PCR analysis confirmed their 
upregulation in IPF fibroblasts (Figure 5B) whilst analysis of ENCODE data 
from human fibroblasts demonstrated their expression using RNA sequencing 
data and two epigenetic markers of active promoters (H3K4me3) and 
transcription (H3K27ac) (Figure 5C). To ascertain whether these are also 
upregulated in IPF lung in situ, we analysed RNA sequencing data of biopsy 
samples obtained from control (n=19) and IPF (n=20) lungs 32 (Supplemental 
Data 8) and showed significant upregulation of LINC01140 but not LINC00960 






Figure 5. Transcriptome analysis shows differential expression of long 
intergenic RNA between control and IPF fibroblasts. (A) The differential 
expression of various classes of genes was examined in 5 control and 5 IPF 
fibroblasts samples in the presence and absence of TGF-β1 stimulated at 24 
hrs, q< 0.05. (B) The differential expression of the two lincRNAs, LINC00960 
and LINC01140 was confirmed by qRT-PCR (n=5). (C) LINC00960 and 
LINC01140 expression was confirmed by comparison with RNA sequencing 
data and the epigenetic marks associated with H3K4me3 (active promoters) 
and H3K27ac (active transcription).  (D) Expression of LINC00960 and 
LINC01140 in the lung biopsies of control (n=19) and IPF patients (n=20). 
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Data in B and D are the mean +/- SEM and statistical significance was 




Long intergenic non-coding RNAs and the regulation TGF-β1-
stimulated PAI-1 release from control and IPF lung fibroblasts  
 
To investigate the function of LINC00960 and LINC01140, we identified 2 
locked nucleic acid based (LNA) antisense sequences against each lincRNA 
that produced 50-85% knockdown following overnight transfection into 
fibroblasts and stimulation with TGF-β1 for 24 hrs (Figure 6A). Following 
exposure to TGF-β1, we observed a significant increase in PAI-1 release from 
both control and IPF fibroblasts (Figure 6B), although the magnitude of this 
response was smaller than that observed in non-transfected cells (Figure 1). 
Knockdown of LINC00960 had no effect upon PAI-1 release from both control 
and IPF fibroblasts. Although one LNA antisense against LINC01140 caused 
a significant reduction in PAI-1 release from control fibroblasts (Figure 6B), 
taken as a whole, it appears that LINC01140 also does not regulate PAI-1 
release. Two scrambled negative LNA controls had no effect on either 
lincRNA expression or PAI-1 release. These results indicate that neither 
LINC00960 nor LINC01140 are required for PAI-1 regulation in control and 




Figure 6. LincRNAs and the regulation of TGF-β1-stimulated PAI-1 
release. Control and IPF fibroblasts were transfected with LNA antisense 
sequences against LINC00960, LINC01140 or scrambled controls overnight. 
Cell were then stimulated with TGF-β1 for 24 hrs prior to (A) isolation of mRNA 
and measurement of LINC00960 or LINC01140 by qRT-PCR or (B) 
measurement of supernatant PAI-1 by ELISA. Data represents the mean +/- 
SEM of five control or IPF individuals. Statistical significance was performed 
using the repeat measures 1-way analysis of variance (ANOVA) with a 
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Long intergenic non-coding RNAs and the regulation of 
PDGF-stimulated proliferation in lung fibroblasts  
 
Following overnight transfection with LNA antisense to LINC00960, 
LINC01140 and the 2 negative controls, we observed no effect upon cell 
count, indicating that this procedure had no immediate action upon cell 
viability (Figure 7A). Following 72 hrs culture, knockdown of LINC00960 and 
LINC01140 caused a significant reduction in proliferation in both non-
stimulated (Figure 7B) and PDGF-stimulated (Figure 7C), which was seen in 
both control and IPF fibroblasts. Generally, no reduction was observed with 
the negative LNA controls. These results indicate that LINC00960 and 


















Figure 7.  LincRNAs and the regulation of the PDGF-AB-stimulated 
proliferation. Control and IPF fibroblasts were transfected with LNA 
antisense sequences against LINC00960, LINC01140 or scrambled controls 
overnight. The cell number was determined at 0 hrs (A) or in non-stimulated 
(B) and PDGF-stimulated (C) samples at 72 hrs. Data represents the mean 
+/- SEM of five control or IPF individuals. Statistical significance was 
performed using the repeat measures 1-way analysis of variance (ANOVA) 
with a Dunnett’s test where * = p <0.05, ** = p <0.01, *** = p <0.001 and **** 








































































































































































































































































































































Long intergenic non-coding RNAs and the regulation of IL-1β-
stimulated IL-6 release in control and IPF lung fibroblasts 
 
We once again demonstrated LNA mediated knockdown of LINC00960 and 
LINC01140 in both control and IPF fibroblasts following overnight transfection 
and 24 hrs exposure to IL-1β (Figure 8A). LINC000960 knockdown had no 
effect upon either IL-1β-induced IL-6 expression (Figure 8B) or IL-6 release 
(Figure 8C) from either control or IPF fibroblasts. In contrast, LINC01140 
knockdown in IPF fibroblasts resulted in a ~ 4-7 fold increase in IL-6 mRNA 
expression (Figure 8B) and ~ 2-3 fold increase in IL-6 release (Figure 8C) 
although the variability between patients meant that this was only significant 
with LNA1. A much smaller ~ 2 fold increase in IL-6 mRNA and protein was 
also seen with LNA2 against LINC01140 in control fibroblasts (Figure 8B/C). 
These observations indicate that LINC01140 is a negative regulator of the IL-
1β-stimulated IL-6 release, particularly in IPF fibroblasts. Interestingly, the 
increased expression of LINC01140 in IPF fibroblasts might explain their 









Figure 8.   LincRNAs and the regulation of the IL-1β-stimulated IL-6 
release. Control and IPF fibroblasts were transfected with LNA antisense 
sequences against LINC00960, LINC01140 or scrambled control overnight. 
Cell were then stimulated with IL-1β for 24 hrs prior to isolation of RNA and 
measurement of LINC00960 or LINC01140 (A) and IL-6 (B) by qRT-PCR or 
(C) measure of released IL-6 by ELISA (mean raw values: 100% control 
fibroblasts, 13633 pg/ml; 100% IPF fibroblasts, 5711 pg/ml). Data represents 
the mean +/- SEM of five control or IPF individuals. Statistical significance was 
performed using the repeat measures 1-way analysis of variance (ANOVA) 
with a Dunnett’s test where * = p <0.05, ** = p <0.01, *** = p <0.001 and **** 
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In this report, we have for the first time investigated the role of lincRNAs in the 
regulation of lung fibroblast function and whether changes in their expression 
might be involved in the development of IPF. In our initial studies, we 
employed high throughput assays to undertake detailed examination of the 
time and concentration responses of control and IPF fibroblasts, examining 
phenotypes associated with IPF 1,3. These included TGF-β1-stimuated PAI-1 
release as a marker of the fibrotic response 33,34, PDGF-induced changes in 
cell numbers as a model of proliferation  35,36 and IL-1β-stimulated IL-6 release 
as a marker of inflammation 31.  
 
As previously reported when using collagen release as a measure of fibrosis, 
we observed no difference in the magnitude of PAI-1 release from control and 
IPF fibroblast in the absence and presence of a maximally effective TGF-β1 
concentration 13. In contrast, the concentration response curves showed a 
significant leftward shift in IPF fibroblasts, indicating that these had increased 
sensitivity to TGF-β1.  
 
In the absence of PDGF, we observed a reduction in the proliferation of IPF 
fibroblasts. Following exposure to PDGF, the small increases and the 
variability of the response between individual fibroblasts samples, meant there 
was no significant difference in the magnitude or concentration dependency 
of the proliferation.  This variability in the PDGF-induced proliferative response 
had previously been observed by Jordana et al 10.  
 
In general, IL-1β is considered to be a potent pro-inflammatory cytokine that 
can induce the release of multiple pro-inflammatory mediators, including IL-6, 
following the activation of the transcription factor, nuclear factor-kappaB (NF-
kB)37. Unlike TGF-β1 and PDGF, the role of IL-1β in the development of IPF 
is yet to be established although there is a report of showing increased levels 
in bronchoalveolar lavage 38. In addition, there are conflicting reports as to 
whether IL-1β elicits profibrotic or antifibrotic activities 39,40. IL-1β was 
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previously shown to drive IL-6 expression in orbital and synovial fibroblasts in 
vitro 30, although nothing is known regarding its effect on lung fibroblasts. As 
anticipated, exposure to IL-1β induced high levels of IL-6 cytokine release in 
both control and IPF lung fibroblasts in a concentration-dependent manner. 
Comparison of the magnitude and the concentration response indicated that 
IPF fibroblasts were less inflammatory than controls. This had also been 
confirmed during a recent meta-analysis of four previous microarrays studies 
in control and IPF fibroblasts which showed repression of inflammation and 
immune pathways 41. Interestingly, this reduced inflammation may explain the 
lack of efficacy observed when corticosteroids and immunosuppressants 
have been examined as therapeutic options for the treatment of IPF 1,3.  
 
Having demonstrated significant differences in fibrotic and inflammatory 
responses between control and IPF fibroblasts, we then proceeded to show 
that this was also reflected at the epigenetic level. To date, the only genome 
wide epigenetic studies in IPF have examined the changes in the profile of 
DNA methylation 14,15, with none having examined histone modifications. We 
therefore measured the distribution of H3K4me1, a marker for priming at 
promoter and enhancer regions that is thought to work through the recruitment 
of multiple chromatin-remodeling complexes 26,27,42. Significantly, we identified 
multiple regions demonstrating differential expression of H3K4me1, with 
unsupervised hierarchical clustering showing a clear separation between 
control and IPF fibroblasts. Although there have been a number of reports 
showing changes is histone marks localised to specific genes implicated in 
IPF 16, this is the first evidence to show genome-wide changes in histone 
modifications and that targeting the acetylation of H3K4 and other histones 
might provide a novel therapeutic strategy. Indeed, this latter contention is 
supported by studies into Brd4, a bromodomain containing protein that can 
bind to acetylated histones and act as a scaffold to attract components of the 
transcriptional machinery. Thus, inhibitors of Brd4 have been shown to 
attenuate migration, proliferation and IL6 release in isolated fibroblasts and 
inhibit fibrosis in a bleomycin-induced model of flung fibrosis 43,44.  
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At the present time, little is known regarding the role of lincRNA either in the 
regulation of fibroblast function or whether changes in their expression are 
associated with the phenotypic changes associated with IPF. The exception 
is studies showing that H19 45,46 and pulmonary fibrosis associated lncRNA 
(PFAL) 47 contribute to lung fibrosis by acting as sponges (and therefore 
inhibitors) for miRNAs.  Using microarray analysis and qRT-PCR, we 
identified 2 lincRNAs, LINC00960 and LINC01140 that were up-regulated in 
IPF compared to control fibroblasts. Given that isolated and cultured 
fibroblasts might not reflect the situation in the whole lung, we were able to 
analyse historical RNA sequencing data obtained from lung biopsies 32 and 
confirm up-regulation of LINC01140 but not LINC00960. Knockdown studies 
indicated that neither appeared to regulate TGF-β1-induced PAI-1, although 
it is not possible to eliminate the possibility that these lincRNAs might regulate 
another aspect of the fibrotic response. In contrast both LINC00960 and 
LINC01140 were positive regulators of proliferation whilst LINC01140 was a 
negative regulator of IL-1β-induced IL-6 release. In the latter case, there was 
a greater elevation in IL-6 release from IPF fibroblasts following LINC001140 
knockdown, possibly reflecting the increased expression of LINC01140 in IPF 
versus control fibroblasts. This increased LINC01140 levels in IPF fibroblast 
might also explain the absence of IL-6 release in non-stimulated IPF 
fibroblasts compared with controls and the shift in the concentration response 
curve in response to IL-1β exposure. Although the mechanism of action is yet 
to be determined, negative regulation of the inflammatory response is 
commonly observed with both lncRNAs and miRNAs including interleukin-7-
antisense (IL7-AS) 48 and miR-146a 49.  
 
Overall, this report is the first to demonstrate that phenotypic differences 
between control and IPF fibroblasts are associated with genome-wide 
changes in histone modifications and increased expression of the lincRNAs, 
LINC00960 and LINC01140. Significantly, we also demonstrate that these 
lincRNAs can regulate fibroblast proliferation and inflammation whilst changes 
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There is accumulating evidence to indicate that long non-coding RNAs 
(lncRNAs) are important regulators of the inflammatory response. In this 
report, we have employed next generation sequencing to identify 14 lncRNAs 
that are differentially expressed in human lung fibroblasts following the 
induction of inflammation using interleukin-1β (IL-1β). Knockdown of the two 
most highly expressed lncRNAs, IL7AS and MIR3142HG, showed that IL7AS 
negatively regulated IL-6 release whilst MIR3142HG was required for IL-8 and 
CCL2 release.  Parallel studies in fibroblasts derived from patients with 
idiopathic pulmonary fibrosis showed similar increases in IL7AS levels, that 
also negatively regulate IL-6 release. In contrast, IL-1β-induced MIR3142HG 
expression was reduced by 8-fold in IPF fibroblasts, with the consequence 
being that MIR3142 knockdown showed no effect upon IL-8 and CCL2 
release. In summary, we have catalogued those lncRNAs that are differential 
expression following IL-1β-activation of human lung fibroblasts and shown 




Interleukin-1β (IL-1β) is a potent pro-inflammatory mediator that is produced 
following activation of one of the multiple inflammasome multi-protein 
complexes. One of the best characterised is the nucleotide-binding 
oligomerization domain-like receptor (NLR) family, pyrin domain-containing 3 
(NLRP3) inflammation, whose activation and subsequent release of IL-1β, 
has been demonstrated in chronic obstructive pulmonary disease, severe 
asthma and respiratory infections (1). Idiopathic pulmonary fibrosis (IPF) is a 
chronic disease characterised by scar tissue accumulation in the lungs 
leading to impaired gas exchange and restricted ventilation (2-4). The 
underlying causes of the disease are still unclear, although persistent 
epithelial injury and/or exposure to pathogens is thought to drive an 
exaggerated wound healing response from fibroblasts, that contributes 
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towards the development and progression of IPF (2,4). In the case of this 
respiratory disease, the role of IL-1β is yet to be established although there is 
a report of showing increased levels in bronchoalveolar lavage (5). In addition, 
there are conflicting reports as to whether IL-1β elicits pro-fibrotic or anti-
fibrotic activities (6,7). IL-1β was previously shown to drive IL-6 expression in 
orbital and synovial fibroblasts in vitro (8), although nothing is known 
regarding its effect on lung fibroblasts. 
 
Non-coding RNAs (ncRNAs) are broadly classified as either short ncRNAs (< 
200 nucleotides) or long ncRNAs (> 200 nucleotides). The microRNA (miRNA) 
family of short ncRNAs are the best characterised and known to induce mRNA 
degradation and/or suppress mRNA translation via RNA interference pathway 
(9). There is now a considerable body of evidence to indicate that miRNAs 
are central regulators of the immune response (10). In particular, induction of 
miR-146a and miR-155 have been shown to be regulators of the inflammatory 
response in multiple cells types (11,12). In contrast, much less is known about 
the function and mechanism of action of lncRNAs which are commonly 
grouped into long intergenic ncRNA (lincRNA) (located between protein 
coding genes), antisense (whose transcription overlaps protein coding genes 
on the opposite strand) and pseudogenes (non-translated versions of protein-
coding genes) (13,14). However, either through interactions with proteins 
and/or RNA/DNA pairing, there it is now accumulating evidence to indicate 
that lncRNAs are novel regulators of multiple biological response, including 
inflammation (15,16). Indeed, studies by ourselves and others have identified 
a number of lncRNAs that are differentially expressed following activation of 
innate immunity, which have been shown to regulate the subsequent 
inflammatory response including PACER (p50-associated COX-2 extragenic 
RNA) (17), THRIL (TNF and hnRNPL related immunoregulatory lincRNA) 
(18), lnc-IL7R (19), IL1β-RBT46 (20), lincRNA-COX2 (21,22), lincRNA-EPS 
(23), lincRNA-Tnfaip3 (24) and IL7AS (25). 
 
At the present time, nothing is known regarding the function of lncRNAs in the 
fibroblast inflammatory response and whether this is changed in IPF. In this 
report, we have employed next generation sequencing to examined the 
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changes in the profile of lncRNA expression following the IL-1β-induced 
inflammatory response from human lung fibroblasts and determined whether 
these regulate the inflammatory response in both control and IPF-derived 
fibroblasts. 
 
3.3. Materials and Methods 
 
Fibroblast source and cell culture  
Control (age = 50 ± 3y; 3 male and 2 females) and IPF fibroblasts (age = 62 
± 1y; 3 male and 2 females) were obtained from Professor Carol Ferghali-
Bostwick (Medical University of South Carolina, USA) and the Coriell Institute 
of Medical Research (Camden, New Jersey, USA). Approval was obtained 
from the Medical Board of the Medical University of South Carolina and the 
Coriell Institute of Medical Research with patients proving material with 
informed consent. All methods were performed in accordance with the 
relevant guidelines and regulations. Neither the control or IPF patients had a 
history of smoking. Isolation of lung fibroblasts was initiated using explants of 
minced lung tissue. Fibroblasts were cultured in DMEM (high glucose, 
pyruvate) growth media (11995-073, ThermoFisher) supplemented with 10% 
(v/v) FBS (Fetal Bovine Serum) (11550356, ThermoFisher), 1% (v/v) 
Penicillin-Streptomycin (11548876, ThermoFisher) and 0.1% (v/v) Fungizone 
(15290-018, ThermoFisher). All cultures were maintained in a 37oC, 5% (v/v) 
CO2 humidified incubator. Upon reaching approximately 80-90% confluency 
cells were washed in sterile 1x PBS (Phosphate Buffered Saline) (P5493, 
Sigma-Aldrich) followed by treatment with StemPro® Accutase® cell 
detachment solution (11599686, ThermoFisher). All experiments were 
performed using cells plated at passage 6 to 7.  
 
Preparation and treatment of fibroblasts used in RNA-seq study  
Control lung fibroblasts (5 x 105 cells) were seeded in 6 cell culture well plates 
(Corning Costar) on day 1 and left overnight. On day 2, the cells were serum-
starved with 2 ml of fresh medium (0.1% FBS) and treated with/without 3 ng/ml 
IL-1β (recombinant, expressed in E. coli, Sigma-Aldrich, I9401-5UG) for 6 
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hours (hrs) before all supernatants were collected and cells were harvested 
for RNA extraction. 
 
RNA isolation and quality control 
For all samples, total RNA was extracted using the RNeasy kit (Qiagen), 
included an on-column DNase treatment (Qiagen), according to the 
manufacturer’s guideline. RNA concentration was determined using the Qubit 
2.0 (Life Technologies). RNA quality was measured using the Agilent 
Bioanalyzer and produced RIN values of >8.0. 
 
Transfection with LNA antisense 
On the day of transfection, 5 µL of HiPerFect (Qiagen) was mixed with 200 µL 
of media without antibiotics, serum or antifungals to prepare the transfection 
mix. LNA GapmeRs were added to 200 µL of the transfection mix at a final 
concentration of 30 nM, placed in 12-well plates and incubated for minimum 
10 mins at room temperature. Fibroblasts were then seeded at a density of 
5x105 cells per well in 200 µL of growth media and incubated with the 
transfection mixes at 37oC, 5% (v/v) CO2 overnight. The next day, 800 µL of 
media (0.1% FBS) was added to the wells to dilute the lipid-LNA complexes 
and reduce the toxicity of the reaction. The cells were stimulated with 3 ng/ml 
of IL-1β and incubated for 24 hrs before harvesting for RNA extraction and 
ELISA (Enzyme-linked immunosorbent assay) analysis. LNA GapmeR 
sequences: Negative Control LNA1 - TCATACTATATGACAG; Negative 
Control LNA2 - GACGGTAAGTAGGCGA; IL7AS LNA1 – 
GGCGTGAGAGTAAAGC; IL7AS LNA2 – GTGCTTAGGCTTAGAG; 
MIR3142HG LNA1 – GTAAACGAGTAGCAGC; MIR3142HG LNA2 – 
GAACATGGTTACGTGT. 
 
Measurement of IL-6, IL-8 and CCL2 release 
Supernatants of cultured lung fibroblasts were collected and used to assess 
secretion of IL-6 and CCL2, using the DuoSet ELISA (DY206 and DY279) 
Development System Kits (R&D Systems Europe, UK) and IL-8 (Ready-SET-
Go!®, eBioscience), following the manufacturer’s instructions.  
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Quantitative PCR validation of lncRNA expression  
For quantitative PCR (qPCR), cDNA libraries were prepared from total RNA 
using the High capacity cDNA RT kit (Applied Biosystems, Life Technologies, 
4368813). Expression of mRNAs and lncRNAs were determined by qPCR 
using the SYBR® Green PCR mix (Applied Biosystems; primers were 
obtained from Sigma-Aldrich). For analysis, the 2−(ΔΔCt) method was used 
to determine relative-quantities of individual mRNAs and lncRNAs which were 
normalized to 18S ribosomal RNA. qRT-PCR primer sequences: 18S – 
AAACGGCTACCACATCCAAG (Forward), CCTCCAATGGATCCTCGTTA 
(Reverse); IL7AS – GTGGACGATGCCAAGTCGT (Forward), 
AGGTGCATGTACAGCAGACG (Reverse); MIR3142HG – 
AGCTTGGAAGACTGGAGACAG (Forward), TCACAGGAACTCACACTCCT 
(Reverse).  
 
Transcriptome analysis of IL-1β-stimulated lung fibroblasts  
Total RNA was extracted from lung fibroblast exposed to either buffer 
(controls) or 3 ng/ml of IL-1β for 6 hrs.  Paired-end 75bp sequencing data 
were obtained using the Illumina HiSeq4000 at the Oxford Genomics Centre 
at the Wellcome Centre for Human Genetics (funded by Wellcome Trust grant 
reference 203141/Z/16/Z). The paired end reads were aligned to the human 
reference genome (hg38) using Hisat2 (version 2.0.4) (26,27) using the 
following command line options: hisat2 -q --dta --rna-strandness FR –x 
<reference-genone.gtf> -1 <forward_strand.fa> -2 <reverse-strand file.fa> –S 
<output.sam>. Output SAM files were then sorted and converted to BAM files 
(samtools sort -@ 8 –o output.bam output.sam) and indexed (samtools index 
–b output.bam) in Samtools (28). The profile of gene expression (using the 
Gencode v27 database and additional novel lncRNA (25)) in the BAM files for 
each samples were determined using Stringtie (29): stringtie <sample.BAM> 
-G <GenCodev26.gtf> -o <samples.gtf> -e -A <sample.txt>. The differential 
expression of gene derived from Gencode v27 and our recently generated list 
of novel lncRNA implicated in the innate immune (25) was assessed with the 
geometric option (DESeq) in Cuffdiff v2.2.1.3 (part of the Cufflinks suite (30)) 
using a significance threshold of q <0.05. The command line options were as 
follows: cuffdiff --FDR=0.05 --min-alignment-count=10 --library-norm-
 94 
method=geometric --dispersion-method=pooled -u <reference_genome.gtf> 
<control_1.bam>,<control_x.bam> <activated_1.bam>,<activated_x.bam> -o 
<output_file_name>.  
 
Principle Component Analysis and Hierarchical Clustering 
The abundance of Gencode v27 defined genes in individual samples was 
defined as the fragments per kilobase exon per million reads mapped (FPKM) 
and determined using Stringtie (RNA) (see above). PCA and hierarchical 
clustering on Gencode v27 protein coding genes demonstrating an expression 
>1 FPKM was performed using Genesis (v1.7.7) (31). Data were log2 
transformed following the addition of 1 FPKM. The threshold for reporting 
gene expression at FPKM >1 is based upon the ability to validate sequencing 
data using qRT-PCR. 
 
Data Access 
RNA sequencing data for control and IL-1β-stimulated fibroblasts can be 
obtained at the Gene Expression Omnibus at GSEXXXXX. 
 


















Differential expression of protein-coding genes in IL-1β-stimulated lung 
fibroblasts 
 
Initial studies were undertaken to examine the IL-1β-induced changes in 
mRNA expression in control fibroblasts (Supplemental Table 1). Selecting 
only those mRNAs showing a fold-change >2, absolute change of 1 FPKM 
and q < 0.05, we identified 453 up-regulated and 261 down-regulated mRNAs 
(Figure 1A). As might be expected, pathway analysis (DAVID Bioinformatics 
resources 6.8; https://david.ncifcrf.gov/home.jsp) showed that the up-
regulated mRNAs were associated with multiple inflammatory pathways 
(Figure 1B). No pathways were highlighted with the down-regulated mRNAs.  
 
Profile of primary miRNA and lncRNAs expression in lung fibroblasts 
 
Before investigating those lncRNAs that were differentially expressed in 
response to IL-1β, we initially examined the profile of lncRNA expression in 
non-stimulated control fibroblasts. As a result of the difficulty in assigning 
sequencing data to either the original mRNA or pseudogenes during 
alignment, the pseudogenes were excluded from this analysis. Using a cut-
off of FPKM > 1 to identify those expressed at physiologically relevant levels, 
we identified 484 lncRNAs that could be divided into 225 lincRNAs and 259 
antisense (Supplemental Table 2), q < 0.05. Amongst the most highly 
expressed lncRNAs were NORAD (Non-coding RNA activated by DNA 
damage), a lncRNA that’s binds Pumilo proteins and regulates genomic 
stability (32,33),  MIR4435-2HG, a host gene (primary miRNA) for miR-4435, 
two small nucleolar host genes (SNHG7/8) and FENDRR (FOXF1 adjacent 
non-coding developmental regulatory RNA) a lncRNA involved in heart and 




Figure 1.  Differential expression of mRNAs and lncRNAs following IL-
1β-stimulation of control lung fibroblasts. (A) Heat map showing the 
differential expression of mRNAs in control fibroblasts following IL-1β 
stimulation for 6 hrs. (B) Pathway analysis of up-regulated mRNAs. (C) Top 
10 most highly expressed lncRNA in non-stimulated control fibroblasts. (D) 
Heat map showing the differential expression of lncRNAs in control fibroblasts 
following IL-1β stimulation for 6 hrs.  
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Differential expression of long noncoding RNAs in IL-1β-stimulated lung 
fibroblasts 
 
To identify those lncRNAs that might mediate the inflammatory response, we 
compared the profile of lncRNA expression in control and IL-1β-stimulated 
fibroblasts at 6 hrs. Using the same criteria as was applied to mRNAs (q < 
0.05, fold change > 2 and absolute expression change > 1 FPKM), we showed 
differential expression of 12 lincRNAs and 2 antisense, of which 7 were up-
regulated and 5 down-regulated (Figure 1D). Of these, IL7AS and 
MIR3142HG showed the largest fold-changes (IL7AS (48-fold) and 
MIR3142HG (157-fold)) and absolute-change (IL7AS (9.2 FPKM) and 
MIR3142HG (5.5 FPKM)) (Supplemental Table 3). These increases in the 
expression of IL7AS and MIR3142HG were confirmed by examination of the 
sequencing data in the IGV genome browser (Figure 2) and qRT-PCR 
analysis (Figure 3A/B). Of relevance, although MIR3142HG is the host gene 
for miR-3142, this also contains miR-146a, a widely reported regulator of 
inflammation and the immune response (11,12). Examination of the 
sequencing coverage in the IGV genome browser indicates that processing 
of this MIR3142HG will produce miR-146a and not miR-3142 (Figure 2).  Also 
amongst the differentially expressed lncRNAs is MIR155HG, the host gene 







Figure 2.   IL-1β-induced expression of IL7AS and MIR3142HG in control 
fibroblasts. Aligned sequencing data (merged BAM files) showing IL7AS and 
MIR3142HG from control and IL-1β-stimulated control fibroblasts was 




IL7AS and MIR3142HG regulate the IL-1β-induced inflammatory 
response  
 
In subsequent studies we investigated the function of IL7AS and MIR3142HG 
in lung fibroblasts during the IL-1β-induced inflammatory response. To this 
end, we identified 2 locked nucleic acid based (LNA) antisense sequences 
against IL7AS (Figure 3A) and MIR3142HG (Figure 3B) that produced 50-
85% knockdown following overnight transfection into fibroblasts and 
stimulation with IL-1β for 24 hrs. Following exposure to IL-1β, we observed 
increased release of the inflammatory mediators IL-6 (Figure 3C/D), IL-8 
(Figure 3E/F) and CCL2 (Figure 3 G/H), Knockdown of IL7AS enhanced the 






















release of IL-6 (Figure 3C) but had no effect upon IL-8 or CCL2 (Figure 3E/G). 
In contrast, MIR3142HG had no effect upon IL-6 (Figure 3D) but significantly 
reduced the release of IL-8 and CCL2 (Figure 3F/H). This indicates that IL7AS 
and MIR3142HG differentially regulate the release of inflammatory mediators 
during IL-1β-induced activation, with IL7AS being a negative regulator of IL6 
release and MIR3142HG a positive regulator of IL8 and CCL2 release. 
 
Figure 3. IL7AS and MIR3142HG regulates the IL-1β-stimulated 
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transfected overnight with LNA antisense sequences against IL7AS (A/C/E/G) 
and MIR3142HG (B/D/F/H) or scrambled (negative) controls. Cell were then 
stimulated with IL-1β for 24 hrs prior to isolation of RNA and measurement of 
IL7AS (A) or MIR3142HG (B) by qRT-PCR or measurement of supernatant 
IL-6 (C/D), IL-8 (E/F) and CCL2 (G/H) by ELISA. Data represents the mean 
+/- SEM of five control individuals. Statistical significance was performed 
using the repeat measures 1-way analysis of variance (ANOVA) with a 




IL7AS and MIR3142HG and the IL-1β-induced inflammatory response in 
IPF fibroblasts 
 
Previous studies have demonstrated differences in the phenotypic responses 
between lung fibroblasts derived from control and IPF patients including a 
recent meta-analysis of microarray data showing repression of inflammation 
and immune pathways in IPF (35). Initial comparison of raw CT values 
obtained from qRT-PCR showed no difference in the baseline expression of 
IL7AS (Control = 23.3 +/- 1.0; IPF = 22.2 +/- 1.1) and MIR3142HG (Control = 
26.35 +/- 0.7; IPF = 27.8 +/- 0.5) between control and IPF fibroblasts. 
Interestingly, although there was no significant difference in the IL7AS 
expression between control and IPF cells following IL-1β stimulation (Control 
= 18.6 +/- 0.8; IPF = 19.4 +/- 1.3), there was an approximate 8-fold reduction 
in the MIR3142HG production in IPF (Control = 19.3 +/- 0.6; IPF = 22.6 +/- 
1.0 : p=0.0225).  
 
Using LNA-based antisense, we once again demonstrated 50-85% 
knockdown of IL7AS (Figure 4A) and MIR3142HG (Figure 4B) following 
overnight transfection into IPF fibroblasts and stimulation with IL-1β for 24 hrs. 
As with control cells, knockdown of IL7AS caused a significant increase in IL-
6 release (Figure 4C) but had no effect upon IL-8 (Figure 4E) or CCL2 
production (Figure 4G). Interestingly, MIR3142HG knockdown had no effect 
upon release of either IL-6, IL-8 or CCL2, which might reflect the 8-fold 
reduction in the IL-1β-induced increased in MIR3142HG seen in IPF 
fibroblasts (Figure 4D/F/Η). 
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Figure 4. IL7AS but not MIR3142HG regulates the IL-β-stimulated 
inflammatory response in IPF fibroblasts. IPF fibroblasts were transfected 
overnight with LNA antisense sequences against IL7AS (A/C/E/G) and 
MIR3142HG (B/D/F/H) or scrambled (negative) controls. Cell were then 
stimulated with IL-1β for 24 hrs prior to isolation of RNA and measurement of 
IL7AS (A) or MIR3142HG (B) by qRT-PCR or measurement of supernatant 
IL-6 (C/D), IL-8 (E/F) and CCL2 (G/H) by ELISA. Data represents the mean 
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the repeat measures 1-way analysis of variance (ANOVA) with a Dunnett’s 




We have for the first time examined the changes in lncRNAs expression 
following activation of human lung fibroblasts with the potent pro-inflammatory 
mediator, IL-1β. This demonstrated differential expression of 14 lncRNAs 
including IL7AS, a syntenically conserved antisense that overlaps and is 
expressed in a bi-directional manner with the promoter of IL-7 (25), as well as 
the host genes for two miRNAs, MIR3142HG (miR-146a) and MIR155HG 
(miR-155). In subsequent functional studies, we employed LNA antisense 
knockdown to examine the role of IL7AS and MIR3142HG, the two most 
highly induced lncRNAs, during the IL-1β-induced inflammatory response. As 
we have previously reported (25,36), IL7AS knockdown was shown to 
increase IL-6 release from both control and IPF-derived fibroblasts, indicating 
that this is a negative regulator. However, in contrast to these earlier reports, 
this action appear to be selective for IL-6, as there was no effect upon the 
release of IL-8 and CCL2 (25,36). Given that MIR3142HG is the host genes 
for miR-146a, it might be speculated that knockdown would lead to a reduction 
in both the full length lncRNAs transcript and processed miR-146a, a well-
characterised miRNA that is thought to negatively regulated the inflammatory 
response through down-regulation of TRAF6 and IRAK1 (37,38). 
Unexpectedly, MIR3142HG knockdown in control fibroblasts resulted in a 
reduction in IL-1β-induced IL-8 and CCL2 release, with no effect upon IL-6, 
indicating that MIR3142HG/miRNA-146a is a positive regulator of the 
inflammatory response in human lung fibroblasts. Of relevance, we have also 
observed cell-type specific actions with IL7AS, this lncRNA showing negative 
regulation of the inflammatory response in monocytes and chondrocytes but 
positive regulation in airway epithelium (25,36). Unfortunately, it is not 
possible to separate the actions of MIR3142HG from those of miRNA-146a 
since miRNA knockdown would also be expected to reduce the levels of the 
host gene. Finally, MIR3142/miR-146a knockdown was shown to have no 
effect upon the IL-1β-induced release of IL-6, IL-8 and CCL2 from IPF-derived 
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lung fibroblasts. However, this is likely to have resulted from 8-fold reduction 
in the IL-1β-induced expression of MIR3142/miR-146a seen in IPF fibroblasts. 
The underlying cause for this reduction in MIR3142/miR-146a expression in 
IPF fibroblasts in unknown although this indicates that changes in 
lncRNA/miRNA expression occurs in disease and that these might under be 
responsible for pathology. 
 
In conclusion, this report has catalogued those lncRNAs that are differentially 
expressed following IL-1β-stimulated activation of human lung fibroblasts and 
demonstrated that 2 lncRNAs, IL7AS and MIR3142HG regulate the 
inflammatory response. Subsequent studies will be required to examine the 
role of the additional lncRNAs and to elucidate the mechanism of action of 
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Aim: Idiopathic pulmonary fibrosis (IPF) is a fatal progressive chronic disease 
characterised by scar tissue accumulation in the lungs leading to impaired gas 
exchange and restricted ventilation. The aetiology and pathogenesis of the 
disease are still unknown, although lung fibroblast have been strongly 
associated with the development and progression of the disease. Pirfenidone 
and nintedanib have recently been licensed for the treatment of IPF although 
their mechanism of action is currently unclear. In this report, we have 
examined the role pirfenidone and nintedanib in the phenotypic response of 
lung fibroblasts obtained from control and IPF patients. 
 
Materials and Methods: Control and IPF fibroblasts were cultured in vitro 
and the fibrotic, proliferative and inflammatory response was determined in 
the presence or absence of pirfenidone or nintedanib by measuring TGF-β1-
induced PAI-1 release, PDGF-AB-induced changes in cells number using the 
CCK-8 viability assay and IL-1β-induced IL6 release, respectively. 
 
Results:  Pirfenidone had no significant effect upon the response to TGF-β1, 
PDGF-AB and IL-1β in neither control or IPF fibroblasts. Nintedanib inhibited 
TGF-β1-induced PAI-1 release and PDGF-AB induced proliferation but had 
no effect upon IL-1β-induced IL-6 release. Inhibition of fibrosis and 
proliferation by nintedanib was seen at lower concentrations in IPF compared 
to control fibroblasts.  
Conclusions: Nintedanib, but not pirfenidone, attenuated the TGF-β1-
induced fibrotic and PDGF-AB proliferative response in human lung 
fibroblasts and was more effective in IPF compared to control patients. Neither 






4.2. Introduction  
The secretion of cytokines and growth factors during the wound healing 
response is thought to influence the activity of fibroblasts and has been 
associated with the development of idiopathic pulmonary fibrosis (IPF), a 
progressive chronic lung disease of unknown aetiology (1). It is now become 
apparent that both the epithelial and inflammatory pathways play a role in the 
development and progression of IPF (2,3). TGF-β1 (transforming growth 
factor β-1), PDGF (platelet-derived growth factor) and IL-1β are amongst the 
cellular mediators that have been shown to regulate the activity of fibroblasts 
during the tissue repair response as they have previously been implicated in 
the induction of fibrogenesis, proliferation and inflammation in IPF (4-6).  
 
TGF-β1 is the most well studied pleiotropic pro-fibrotic cytokine and is thought 
to be the key player in the pathogenesis of pulmonary fibrosis (7). TGF-β1 
plays a central role in events driving the fibrotic response such as fibroblast 
activation and myofibroblast differentiation (8,9), extracellular matrix (ECM) 
production (10,11) and epithelial-mesenchymal-transition (EMT) (12). 
Elevated expression of PDGF, a potent fibroblast mitogen and 
chemoattractant, is thought to be another ‘master switch’ in the development 
of IPF (13). PDGF isoforms were shown to drive the proliferation (14) and 
migration (15) of fibroblasts in fibrosis as well as the secretion of inflammatory 
cytokines (16). The role of IL-1β in the development of IPF remains unclear 
as not much is known about the activity of this pro-inflammatory cytokine 
during fibrosis. Kolb et al. has reported an indirect pro-fibrotic activity for IL-
1β in vivo (17), while increased levels were detected in the bronchoalveolar 
lavage (BAL) of IPF patients (18). Interestingly, although it was shown to 
directly stimulate collagen expression in fibroblasts (19), another report has 
shown inhibition (20). A more recent study suggests that IL-1β has an anti-
fibrotic effect on dermal and lung fibroblasts in vitro (21).  
 
The lack of understanding regarding the underlying mechanisms of IPF makes 
the development of effective drug treatments particularly challenging. 
Νintedanib (BIBF1120) was approved for use in 2014 after the completion of 
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the INPULSIS trials (22). This small molecule was shown to slow the 
progression of IPF through inhibition of multiple receptor tyrosine kinases 
including vascular endothelial growth factor (VEGFR), fibroblast growth factor 
(FGFR) and platelet-derived growth factor (PDGFR) both in vivo (23,24) and 
in vitro (25,26). Following the satisfactory results of the ASCEND trial (27), 
pirfenidone was also approved in 2014 as the first specific anti-fibrotic therapy. 
Pirfenidone is a novel anti-fibrotic, anti-oxidant and anti-inflammatory drug 
which is thought to reduce TGF-β1 expression (28-30), although its exact 
mechanism of action is still unclear. Pirfenidone was shown to attenuate 
fibrosis by reducing proliferation as well as α-smooth muscle actin (α-SMA) 
and collagen levels in fibroblasts in vitro (26,31,32). Pirfenidone has also 
demonstrated anti-fibrotic activities in the bleomycin animal models, through 
attenuating fibrocyte recruitment to the lungs and the secretion of several 
cytokines (33,34), as well as PDGF (35) and TGF-β1 (28) synthesis.  
 
The secretion of these fibrotic mediators during tissue repair has been 
established as a crucial element in the development of IPF, yet more 
information is required on how each of these compounds individually influence 
lung fibroblast activation. We have therefore examined the effect of the 
nintedanib and pirfenidone upon the fibrotic, proliferative and inflammatory 
responses in lung fibroblasts obtained from both control and IPF patients.  
 
 
4.3. Materials and Methods 
Fibroblast source and cell culture  
Control (age = 47 ± 7y; 1 male and 2 females) and IPF fibroblasts (age = 63 
± 1y; 2 males and 1 female) were obtained from Professor Carol Ferghali-
Bostwick (Medical University of South Carolina, USA) and the Coriell Institute 
of Medical Research (Camden, New Jersey, USA). Neither the control or IPF 
patients had a history of smoking. Isolation of lung fibroblasts was initiated 
using explants of minced lung tissue. Fibroblasts were cultured in DMEM (high 
glucose, pyruvate) growth media (11995-073, ThermoFisher) supplemented 
with 10% (v/v) FBS (Fetal Bovine Serum) (11550356, ThermoFisher), 1% (v/v) 
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Penicillin-Streptomycin (11548876, ThermoFisher) and 0.1% (v/v) Fungizone 
(15290-018, ThermoFisher). All cultures were maintained in a 37oC, 5% (v/v) 
CO2 humidified incubator. Upon reaching approximately 80-90% confluency 
cells were washed in sterile 1x PBS (Phosphate Buffered Saline) (P5493, 
Sigma-Aldrich) followed by treatment with StemPro® Accutase® cell 
detachment solution (11599686, ThermoFisher). All experiments were 
performed using cells plated at passage 6 to 7. 
 
Plating and treatments of fibroblasts for pharmacological studies  
1 x 104 cells were plated in 96-cell culture wells on day 1 and allowed to rest 
overnight. On day 2, cells were serum-deprived by reducing FBS to 0.1% in 
200 μl of media before treatment application. Fibroblasts were then treated 
with the required concentration of TGF-β1 (recombinant human, expressed in 
Chinese hamster ovary cell line, R&D systems, 240-B-002/CF), IL-1β 
(recombinant, expressed in E. coli, Sigma-Aldrich, I9401-5UG), pirfenidone 
(C12H11NO, Sigma-Aldrich, P2116) and nintedanib (BIBF1120, C31H33N5O4, 
Cayman Chemical, 11022) and incubated for the required time before 
supernatants were collected for protein quantification assessment.  
 
Measurement of IL-6 and PAI-1 release 
Supernatants of cultured lung fibroblasts were collected and used to assess 
secretion of IL-6 and PAI-1, using the DuoSet ELISA (Enzyme-linked 
immunosorbent assay, DY206 and DY1786) Development System Kits (R&D 
Systems Europe, UK) following the manufacturer’s instructions. Absorbance 
was measured at 450 nm with wavelength correction at 570 nm using a 
microplate reader (Fluostar Optima, BMG Labtech). 
 
Cell Proliferation 
Lung fibroblast proliferation was evaluated by measuring cell viability with the 
Cell Counting Kit-8 (CCK-8, Sigma-Aldrich). Cells (5000) were seeded in a 
96-well plate and incubated overnight in 100 μl growth media (10% FBS). The 
following day, the cells were serum-deprived and treated with the indicated 
concentration of PDGF-ΑΒ (recombinant human, E. coli derived, R&D 
systems, 222-AB-010), pirfenidone (C12H11NO, Sigma-Aldrich, P2116) and 
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nintedanib (BIBF1120, C31H33N5O4, Cayman Chemical, 11022) and incubated 
for the indicated time. Before the end of each assay, 10 μl of the CCK-8 
solution was added into a final volume of 100 μl growth media and incubated 
for 2 hours before absorbance was measured using a microplate reader 
(Fluostar Optima, BMG Labtech). The absorbance wavelength was measured 
at 450 nm and 600 nm which was then subtracted during data analysis.  
 
Statistical Analysis 
All statistical analysis and graphs were generated using GraphPad Prism 7 
software. Statistical significance was determined using repeated measures 
ANOVA with a Dunnett’s multiple comparisons test (each column is compared 
to the positive control column), where * p < 0.05, ** p < 0.01, *** p < 0.001 and 






















To determine the mechanism of action of pirfenidone and nintedanib in 
fibrosis, proliferation and inflammation, we assessed their concentration 
dependent action upon TGF-β1-induced PAI-1 release, PDGF-AB-induced 
cell number and IL-1β-stimulated IL-6 release at 72 hours (hrs), respectively. 
In addition, we compared their action in lung fibroblasts derived from control 
and IPF patients to assess whether they had differential action. The 
concentration ranges of pirfenidone (10 uM – 1000 uM) and nintedanib (3 nM 
– 3000 nM) were selected based on previous studies investigating their 
biological actions (25,26,36-38). 
 
Effect of pirfenidone and nintedanib on the fibrotic response 
PAI-1 levels have been shown to be increased in the lungs of patients with 
diverse lung diseases including IPF, where it is considered to exert a pro-
fibrogenic effect (39). Furthermore, TGF-β1 was previously shown to increase 
PAI-1 expression in several cell types including lung fibroblasts and the 
release of PAI-1 is considered to be a marker of fibrosis (40-43).  
 
Exposure to TGF-β1 induced a significant increase in release of PAI-1 from 
both control and IPF fibroblasts. Pirfenidone treatment had no effect upon 
non-stimulated or TGF-β1-induced PAI-1 release from either control or IPF 
fibroblasts (Figure 1A). Although nintedanib had no impact upon PAI-1 release 
from non-stimulated cells, it attenuated TGF-β1-induced PAI-1 generation 
from both control (46.6%) and IPF (56.7%) fibroblast at 3000nM (Figure 1B). 
It appeared to be more effective against IPF fibroblast since significant 
inhibition was also seen at 300nM (75%) and 1µM (68%). These observations 
indicate that nintedanib but not pirfenidone, inhibits the fibrotic response and 









Figure 1. Concentration dependent effect of pirfenidone and nintedanib 
upon PAI-1 release from control and IPF lung fibroblasts. Human control 
and IPF lung fibroblasts were exposed to the indicated concentrations of 
pirfenidone (A) and nintedanib (B) for 72 hrs with and without 3 ng/ml TGF-
β1. Each column represents the mean ± SEM of 3 independent patients of 
which 3 replicates were used to calculate the mean of each data point. All 
columns are compared to the positive control treated with TGF-β1 and no 
antagonist. Columns treated with pirfenidone or nintedanib alone serve as 

















































































































































Effect of pirfenidone and nintedanib on proliferative response 
PDGF-A and PDGF-B are the predominantly expressed isoforms of the PDGF 
family implicated in fibrosis where they are thought to promote fibroblast 
proliferation (24,44); while evidence support the concept that cross-talk 
between TGF-β1 and PDGF may further modulate the progression of 
irreversible scarring (45).   
As expected, incubation of lung fibroblasts in the presence of PDGF-AB 
promoted cell proliferation in both control and IPF fibroblasts (Figure 2). 
Pirfenidone had no significant effect upon non-stimulated or PDGF-AB-
induced cell proliferation from either control or IPF fibroblasts (Figure 2A). 
Nintedanib had also no impact upon cell proliferation from non-stimulated cells 
but attenuated PDGF-AB-induced proliferation from both control and IPF 
fibroblast in a concentration dependent manner, reducing cell counts to 16% 
and 32% at 3 μM, respectively (Figure 2B). Notably, nintedanib significantly 
inhibited proliferation at lower concentrations in IPF fibroblasts starting at 30 
nM compared to 300 nM in control fibroblasts. These observations indicate 
that nintedanib but not pirfenidone, attenuates proliferation and that IPF 










Figure 2. Concentration dependent effect of pirfenidone and nintedanib 
on cell proliferation in control and IPF lung fibroblasts. Human control 
and IPF lung fibroblasts were exposed to the indicated concentrations of 
pirfenidone (A) and nintedanib (B) for 72 hrs with and without 100 ng/ml 
PDGF-AB. Each column represents the mean ± SEM of 3 independent 
patients of which 3 replicates were used to calculate the mean of each data 
point. All columns are compared to the positive control treated with PDGF-AB 
and no antagonist. Columns treated with pirfenidone or nintedanib alone serve 















































































































































Effect of pirfenidone and nintedanib on inflammatory response 
IL-1β was previously shown to drive IL-6 expression in orbital and synovial 
fibroblasts in vitro (46,47), however not much is known regarding its effect on 
lung fibroblasts. As anticipated, exposure to IL-1β induced high levels of IL-6 
cytokine release in both control and IPF lung fibroblasts (Figure 3). Neither 
pirfenidone or nintedanib had an effect upon non-stimulated or IL-1β-induced 
IL-6 release from either control or IPF fibroblasts (Figure 3) and indicates that 
neither drug acts by attenuating the inflammatory response. 
 
Figure 3. Concentration dependent effect of pirfenidone and nintedanib 
upon IL-6 release from control and IPF lung fibroblasts. Human control 
and IPF lung fibroblasts were exposed to the indicated concentrations of (A) 
pirfenidone and (B) nintedanib for 72 hrs with and without 3 ng/ml IL-1β. Each 
column represents the mean ± SEM of 3 independent patients of which 3 
replicates were used to calculate the mean of each data point. All columns 
are compared to the positive control treated with IL-1β and no antagonist. 
Columns treated with pirfenidone or nintedanib alone served as negative 
controls.  
 









































































































































In this report, we examined the concentration-dependent effects of nintedanib 
and pirfinedone in TGF-β1, PDGF-AB and IL-1β activated lung fibroblasts by 
measuring PAI-1, cell viability and IL-6, respectively. The highest 
concentration of nintedanib was 3000 nM, which was higher than the 1000 nM 
employed in previous studies in vitro (24-26). We also initially employed a 
supra-maximal concentration pirfenidone at 10000 μM  but as a result of 
toxicity, reduced this to 1000 μM suggested by other authors (26,31).  
 
The TGF-β1-induced PAI-1 release of lung fibroblasts was not inhibited by 
pirfenidone. The inability of pirfenidone to reduce the TGF-β1-induced 
response contrasts observations by other groups showing pirfenidone 
inhibiting the expression of TGF-β1-induced proteins such as collagen, α-
smooth muscle actin (α-SMA) and connective tissue growth factor (29,31,48). 
In contrast, nintedanib significantly reduced PAI-1 release of lung fibroblasts, 
with a more potent effect on IPF lung fibroblasts. This finding is in line with 
previous studies demonstrating the inhibitory activity of nintedanib on TGF-
β1-induced fibronectin and α-SMA production (26,49). 
 
Treatment with pirfenidone showed no significant reduction in PDGF-AB-
induced cell proliferation. Significant inhibition in cell viability of control 
fibroblasts was noted upon treatment with higher concentrations of 
pirfenidone although this effect is likely to be mediated by the cellular toxicity. 
Although pirfenidone is not primarily known as an anti-proliferative agent, it 
was found to reduce lung fibroblast proliferation at higher concentrations in 
vitro by Conte and co-workers (31) as well as cardiac fibroblasts (50), stromal 
cells (26) and tenon’s fibroblasts (51). Nintedanib as a potent inhibitor of 
VEGFR, FGFR and PDGFR, effectively reduced cell viability in both control 
and IPF fibroblasts. Notably, the action of nintedanib was observed at lower 
concentrations in IPF lung fibroblasts compared to healthy controls. 
Interestingly, a previous study by Hostettler et al. suggests greater sensitivity 
of nintedanib by control fibroblasts (25) whereas a more recent study by 
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Lehtonen et al. does not report a significant difference between stromal cells 
derived from control and IPF lungs (26).  
Neither pirfenidone nor nintedanib inhibited the IL-1β-induced release of IL-6 
from control and IPF lung fibroblasts. Although pirfenidone demonstrated an 
inhibitory activity towards IL-6 levels in previous studies (52-54), no other 
evidence regarding the inhibition of the IL-1β-induced release of this pro-
inflammatory cytokine exist by either of these antagonists.  
In summary, the data presented in this study suggests that TGF-β1, PDGF-
AB and IL-1β are potent stimuli of lung fibroblasts. Pirfenidone did not inhibit 
the responses to TGF-β1, PDGF-AB and IL-1β, whereas nintedanib 
demonstrated a significant inhibitory effect on PAI-1 release and cell 
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5.1. General Discussion 
 
The hypothesis of this study was that lncRNAs regulate the function of 
fibroblasts in normal and IPF human lungs. The overall results of this study 
support the hypothesis as several lncRNAs were identified to be differentially 
expressed in the IPF lungs as well as in response to pro-fibrotic and pro-
inflammatory activation in vitro. Additionally, the functional roles of 4 lncRNAs 
were confirmed using knockdown studies and were found to regulate the 
activity of human lung fibroblasts. 
 
Prior to studying lncRNA expression and function, the initial stages of this 
project focused on the pharmacological characterisation of the responses to 
TGF-β1, PDGF-AB and IL-1β. The effect of these agonists on adult primary 
human lung fibroblasts provided a better understanding of the optimal 
conditions required for examining changes in mRNA and lncRNA expression 
in subsequent studies. These experiments also provided valuable information 
as to the phenotypic differences between control and IPF fibroblasts. Based 
upon these investigations, we showed that IPF fibroblasts demonstrated a 
more fibrotic and a less inflammatory and proliferative profile than control 
fibroblasts. 
 
As demonstrated in previous studies, TGF-β1 is a potent activator of PAI-1 
(Kutz et al., 2001; Murakami et al., 2006; Omori et al., 2016; Takakura et al., 
2012) and was therefore used as a measure of the fibrotic response in our 
studies. Upon TGF-β1 stimulation both control and IPF lung fibroblasts 
presented a significantly elevated release of the pro-fibrotic protein PAI-1. 
Most importantly, IPF fibroblasts demonstrated significantly higher sensitivity 
to TGF-β1 concentrations compared to control fibroblasts as demonstrated by 
their logEC50 values. PAI-1 release was also elevated over time when 
incubated with 3 ng/ml TGF-β1, a concentration found to effectively activate 
the fibroblasts used in this study; similar concentrations in the range of 2-5 
ng/ml were previously reported by other studies (RAghu et al., 1989; Aschner 
et al., 2014; Porte and Jenkins, 2014; Omori et al., 2016).  
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Incubation of lung fibroblasts with various concentrations of PDGF-AB 
promoted cell proliferation, a finding consistent with previous studies (Hetzel 
et al., 2005). However, no significant difference was observed between control 
and IPF fibroblasts in response to PDGF-AB exposure, possibly due to the 
high variability between cell populations. As these fibroblasts were isolated 
from different patients, variability in their response to stimuli was anticipated, 
which is an issue that could potentially be addressed by increasing the 
number of biological replicates. Lung fibroblasts also demonstrated a time-
dependent increase in cell numbers over the 72-hour period following 
exposure to 100 ng/ml PDGF-AB. Similar concentrations of PDGF (50-120 
ng/ml) have previously been shown to increase the proliferative activity of 
various cell types including fibroblasts (Makarov et al., 2013; Wollin et al., 
2014) whilst other studies have demonstrated an effect at  lower 
concentrations (Hetzel et al., 2005; Vij et al., 2008). Interestingly, unstimulated 
control fibroblasts isolated from healthy lungs demonstrated significantly 
higher proliferative capacity compared to unstimulated IPF fibroblasts. This 
observation is in line with previous findings (Ramos et al., 2001; Hetzel et al., 
2005), although other studies reported that IPF fibroblasts proliferate 
significantly faster (Jordana et al., 1988; Marudamuthu et al., 2015). The 
slower growth rate of IPF fibroblasts may be explained by their increased 
basal rate of spontaneous apoptosis as reported by Ramos et al. (Ramos et 
al., 2001). However, this may raise more questions regarding the activity and 
fate of IPF fibroblasts during the disease as well as the relation between 
increased programmed cell death and fibroblastic foci formation in the scarred 
lung. 
 
IL-1β (1-10 ng/ml) was previously shown to promote IL-6 expression in orbital 
and synovial fibroblasts in vitro (Chen et al., 2005; Miyazawa et al., 1998), 
however no studies have focused on its effect on IL-6 in lung fibroblasts. 
Exposure to IL-1β induced high levels of IL-6 cytokine release in both control 
and IPF lung fibroblasts in a concentration-dependent manner. However, in 
contrast to the TGF-β1 response, control fibroblasts exhibited significantly 
higher sensitivity to IL-1β treatment compared to IPF fibroblasts, indicating a 
lower inflammatory profile for IPF fibroblasts. A review of transcriptome 
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studies by Plantier et al. also showed repression of inflammatory and immune 
pathways in IPF fibroblasts (Plantier et al., 2016). Examination of the time 
course indicated that IL-6 levels were also considerably elevated in both 
unstimulated and IL-1β-activated control fibroblasts compared to the 
corresponding time points in IPF fibroblasts. This finding differs from a recent 
study showing no significant difference in basal IL-6 levels between control 
and IPF fibroblasts (Schuliga et al., 2017).  
 
The effects of the IPF drugs nintedanib and pirfenidone on TGF-β1, PDGF-
AB and IL-1β-activated lung fibroblasts were also investigated. Pirfenidone 
elicited no effect on the activity of control or IPF fibroblasts; while nintedanib 
inhibited the TGF-β1-induced fibrotic response and PDGF-AB-induced 
proliferative response but not the IL-1β-induced inflammatory response. 
Interestingly, phenotypic differences between control and IPF fibroblasts were 
also demonstrated in these experiments, where nintedanib was found to have 
a significant inhibitory effect on IPF fibroblasts at lower concentrations, both 
in reducing PAI-1 levels and cell proliferation compared to the controls. 
However, although pirfenidone did not reduce proliferation or PAI-1 and IL-6 
release, this does not reflect its inability to inhibit other IPF-related events. 
Indeed, pirfenidone was previously shown to attenuate the fibrotic response 
by reducing proliferation as well as α-SMA and pro-collagen mRNA and 
protein levels in lung fibroblasts (Conte et al., 2014).  
 
The phenotypic differences between control and IPF lung fibroblasts 
discussed above were also reflected at the epigenetic level. Using a chromatin 
immunoprecipitation (ChIP)–specific antibody for the histone modification 
H3K4me1 in combination with next-generation high-throughput sequencing, 
we examined the genome-wide distribution profile of H3K4me1 in 
unstimulated control and IPF lung fibroblasts. The histone modification 
H3K4me1 is a marker of ‘poised’ promoter and enhancer regions and it is 
therefore considered as a ‘window of opportunity’ for transcription (Calo and 
Wysocka, 2013). A clear distinction was observed between the control and 
IPF lung fibroblasts using unsupervised hierarchical clustering, indicating a 
difference in the basal epigenetic state of the two cell groups which might 
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explain their different responses to stimuli such as TGF-β1 and IL-1β, as well 
as their basal proliferative activity. This is the first genome-wide study to 
investigate the profile of H3K4me1-enriched DNA regions in IPF fibroblasts or 
indeed any other histone markers, although previous epigenetic studies 
showed altered DNA methylation in IPF lung tissues (Sanders et al., 2012) 
and IPF fibroblasts (Huang et al., 2014).  
 
Upon establishing the phenotypic and epigenetic differences between control 
and IPF lung fibroblasts, the role of lncRNAs in the regulation of IPF was 
investigated. As novel mediators of gene regulation, the expression of 
lncRNAs has not been explored previously in IPF lung fibroblasts; therefore, 
investigating their expression and ultimately their role in control and IPF 
fibroblasts was the primary aim of this study. Having characterised the 
different phenotypic and epigenetic profiles of the two cell populations in the 
prior experiments, it was interesting to investigate whether these might be 
attributed to the expression of lncRNAs.  
 
The transcriptomic profiles of non-stimulated and TGF-β1–stimulated control 
and IPF fibroblasts were investigated using the Affymetrix GeneChip™ 
Human Transcriptome Arrays 2.0. This is the highest resolution microarray for 
gene expression profiling with over 6 million probe sets covering both protein 
and non-protein coding transcripts. The last and only gene profiling study 
which focused on investigating gene expression in ‘fibrotic’ fibroblasts in 
response to TGF-β1 exposure was completed more than 10 years ago 
(Renzoni et al., 2004). However, this study used a much older version of 
microarray technology and did not examine changes in lncRNA expression. 
Also notable is that this study did not use only IPF fibroblasts but rather a 
combination of IPF and scleroderma-associated fibroblasts which were 
referred to as ‘fibrotic’ fibroblasts. In our study, TGF-β1 activation stimulated 
the expression of several pro-fibrotic genes in both the control and IPF 
fibroblasts, however there was not a significant difference in the expression of 
either mRNAs or lncRNAs between the two groups at the transcriptomic level. 
This is consistent with the findings of Renzoni et al. (Renzoni et al., 2004), 
where no substantial difference was observed between control and fibrotic 
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fibroblasts in response to TGF-β1. Hence, the profiles of non-stimulated 
control and IPF fibroblasts were also compared. Two lncRNAs namely 
LINC00960 and LINC01140 were identified to be significantly differentially 
expressed in IPF fibroblasts and their elevated expression was confirmed by 
qRT-PCR. Notably, analysis of published RNA-seq data from biopsy samples 
showed that LINC00960 and LINC01140 were expressed in both control and 
IPF lung tissue, although only LINC01140 demonstrated significant 
upregulation in the IPF lung. The reasons for these differences are unclear 
although they may be attributed to the fact that lung biopsies contain a mixture 
of cells not just fibroblasts, and that lncRNAs expression is typically cell-
specific. However, the expression of both lncRNAs in lung tissue provided 
further evidence that they are present in human lungs and may have an 
important role in IPF.  
 
The role of LINC00960 and LINC01140 in control and IPF fibroblasts was 
investigated using knockdown studies. Very little is known about these 
lncRNAs and nothing is reported regarding their functional roles, with the 
exception of just one study which has identified LINC01140 as a biomarker 
for the prognosis of gastric cancer (Song et al., 2017). LINC00960 and 
LINC01140 knockdown failed to affect the TGF-β1-induced PAI-1 response, 
However, LINC00960 and LINC01140 were shown to be positive regulators 
of proliferation both in the presence and absence of PDGF-AB activation. This 
finding may not be surprising as several other lncRNAs were previously found 
to regulate cell proliferation in various cell types (Wang et al., 2016; Shao et 
al., 2017; Park et al., 2018) as well as fibroblasts (Beermann et al., 2018). 
LINC01140 was also found to be a negative regulator of the inflammatory 
response as its knockdown significantly increased IL-6 expression and 
release, particularly in IPF lung fibroblasts. This observation may explain how 
the elevated expression of LINC01140 in IPF fibroblasts leads to the reduced 
inflammatory profile, when compared to controls. 
 
The transcriptomic profile of control lung fibroblasts in the presence and 
absence of the potent pro-inflammatory cytokine IL-1β was also examined for 
the first time. RNA-seq revealed differential expression of several mRNAs and 
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lncRNAs, particularly genes associated with inflammatory pathways. Amongst 
these genes, expression of the lncRNAs IL7AS and MIR3142HG exhibited the 
highest upregulation and their function was investigated further in subsequent 
experiments. IL7AS was found to regulate IL-6 release in both control and IPF 
fibroblasts, a finding similar to previous studies demonstrating the regulatory 
activity of this lncRNA in the inflammatory response (Pearson et al., 2016; 
Roux et al., 2017). MIR3142HG knockdown attenuated IL-8 and CCL2 protein 
release in control fibroblasts, thus demonstrating a positive regulatory role in 
the inflammatory response. MIR3142HG is a host gene for miR-146a and 
therefore its knockdown may inevitably reduce the expression of this miRNA. 
Interestingly, previous studies have found that expression of miR-146a exerts 
an anti-inflammatory effect and is therefore considered a negative regulator 
of the inflammatory response (Meisgen et al., 2014; Bhatt et al., 2016; Roos 
et al., 2016). Contrastingly, a recent knockout study by Pfeiffer et al. showed 
that miR-146a positively regulates inflammation in endothelial cells (Pfeiffer et 
al., 2017). The contradictive findings may not be unusual given that 
lncRNAs/miRNAs are known to exert cell-specific functions; thus, the 
functions of miR-146a are most likely tightly regulated by its lncRNA host 
gene. Knockdown of MIR3142HG did not affect the expression of any of the 
pro-inflammatory proteins measured in IPF fibroblasts which may be 
attributed to the fact that the expression of MIR3142HG was already reduced 
compared to controls following IL-1β activation and thus no appreciable 
difference was observed. The reduced expression of this lncRNA in IPF 
fibroblasts is another interesting finding which may give an insight into the 
transcriptional differences between control and IPF fibroblasts. As discussed 
above, IPF fibroblasts were shown to have a reduced inflammatory profile 
compared to the controls which were more sensitive to IL-1β activation and 
released elevated levels of IL-6. Interestingly, MIR3142HG was shown to be 
a positive regulator of inflammation and its expression was particularly 
elevated in control fibroblasts, which may raise further questions as to how 





5.2. Future work and directions  
The experiments described in this thesis have focused upon examining the 
role of lncRNAs in both non-stimulated control and IPF lung fibroblasts, as 
well as both cell types exposed to stimuli that drive phenotypes associated 
with IPF. However, considering the limitations of the study, these observations 
have raised further questions which require consideration.  
 
The project characterised the effects of TGF-β1, PDGF-AB and IL-1β on 
control and IPF lung fibroblasts which are three of several proteins associated 
with the development of IPF. Future studies might look at other cytokines and 
mediators that have been implicated in the development of IPF. Moreover, 
increasing the number of biological replicates would enhance the statistical 
robustness of all experiments and resolve issues related to the variability 
between patient responses. In addition, although the principal focus of the 
project was upon examining the differences in fibrotic response, we also 
uncovered significant differences in the inflammatory response between 
control and IPF fibroblasts. The observation that IPF fibroblasts have a 
reduced inflammatory profile compared to the controls raised key questions 
regarding the role of inflammation in the development of IPF. Interestingly, 
previous attempts to treat IPF with immunosuppressants have failed and have 
even been shown to exacerbate IPF in several cases (Spagnolo et al., 2015a). 
Although evidence suggests the immune response is suppressed in IPF 
fibroblasts, it appears that the presence of a prominent immune inflammatory 
infiltrate in IPF lungs plays a potential role in early disease progression 
(Balestro et al., 2016). Hence, the role of inflammation and more generally the 
immune response in IPF is still unclear and largely unexplored. Whether the 
role of the immune response changes as the disease progresses and how it 
affects the activation of different cells in human lungs has yet to be explored.  
  
The epigenetic landscape of control and IPF fibroblasts also showed distinct 
differences as observed by the H3K4me1-enriched DNA regions. However, 
there was no correlation between the H3K4me1-associated regions and the 
lncRNAs or mRNAs that were differentially expressed in IPF fibroblasts. 
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Although H3K4me1 provides insight regarding DNA regions associated with 
promoters and enhancers that are poised for transcription, future studies 
might look at other common histone markers such as those for active 
promoters (H3K4me3) or active transcription (H3K27ac). Epigenetic 
modifications are gaining increasing interest as therapeutic targets as 
indicated by the success of histone deacetylase (HDAC) inhibitors and DNMT 
inhibitors as cancer treatments (Pfister and Ashworth, 2017).  
 
The transcriptomic data in this study revealed hundreds of differentially 
expressed genes in response to exposure to TGF-β1 and IL-1β, of which four 
lncRNAs were selected for further investigation. However, although modern 
array and sequencing technology are incredibly powerful, one of the 
limitations that should be considered is that they only provide a snapshot into 
the transcriptional state of the cells at a very specific point in time. As there is 
a constant turnover of transcripts in a cell reflecting changes in gene 
expression, this inevitably limits the capacity of sequencing to resolve 
changes in cellular activity over time. As such, examining the transcriptome of 
IPF fibroblasts at different time points may yield better insights as to the overall 
gene expression activity, which would be otherwise overlooked.    
 
One of the most important aspects of this study were the functional studies 
around the four differentially expressed lncRNAs. Evidently, more functional 
and mechanistic studies are essential to further understand the function of 
these lncRNAs. For example, knockdown of LINC00960 and LINC01140 did 
not demonstrate a significant effect on the PAI-1 release which was a 
measure of the fibrotic response. However, it is unknown if they regulate other 
proteins associated with the fibrotic response which was not possible to 
examine in this project. Likewise, although LINC01140, IL7AS and 
MIR3142HG were shown to regulate cytokines of the inflammatory response, 
only a number of cytokines were investigated and therefore the full effect of 
these lncRNAs on gene expression is unclear. As such, employing array or 
sequencing technology on these lncRNA knockdown samples would be of 
great interest to gain an overview of the effect they have on global gene 
expression.  
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Very little is known about these lncRNAs and therefore further functional 
studies should focus not just on which genes are affected by their expression, 
but also their mechanism-of-action. With the exception of IL7AS, it is currently 
unknown whether these lncRNAs are located in the nucleus or the cytoplasm. 
IL7AS was previously found to be enriched in the nucleus in THP-1 and A549 
cell lines (Roux et al., 2017). Nuclear-cytoplasm RNA fractionation could be 
used to determine the subcellular distribution of the other lncRNAs which 
would provide some indication as to their potential mechanism. In the longer 
term, it would be crucial to investigate protein-lncRNA interactions to 
determine the mechanism by which they function.  
 
Examining isolated fibroblasts in vitro enables the investigation of these cells 
individually, however it is equally important to examine how fibroblasts interact 
with other cells, as well as under exposure to multiple physiologically relevant 
signals and stimuli. Investigating the in vivo effects of lncRNAs in the 
bleomycin model of fibrosis may thus generate a useful insight into such 
effects; however, the poor conservation of lncRNAs between species may 
present further challenges in this context. One potential means to overcome 
this would be to examine the expression profile of lncRNAs in cells isolated 
from lung tissue following dissociation and separation using fluorescence-
activated cell sorting (FACS). However, although this approach offers the 
prospect of more physiologically representative cell populations, the lack of 
well characterised fibroblast-specific markers hinders reliable sorting of 
sufficient numbers of fibroblasts for downstream applications.  
 
Finally, as a consequence of their cell/tissue-specific expression, the 
identification of lncRNAs that drive the activity of IPF lung fibroblasts may 
present a great opportunity for the development of novel treatment strategies. 
Several oligonucleotide antisense therapeutics have already proven 
successful and are being administered to patients, while nucleic acid-targeting 
drugs have demonstrated great potential in targeting lncRNAs in cancer (Arun 
et al., 2018). Better delineating the functions of lncRNAs in lung fibroblasts 
may thus render them as potential targets for pharmacological intervention for 
IPF.  
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• Control and IPF fibroblasts were stimulated in a time-dependent 
manner in response to TGF-β1, PDGF-AB and IL-1β 
• IPF fibroblasts demonstrated a more fibrotic and a less inflammatory 
and proliferative profile compared to control fibroblasts 
• A clear distinction was observed between the H3K4me1-enriched DNA 
regions of control and IPF fibroblasts  
• Differential gene expression of several mRNAs and lncRNAs was 
observed upon TGF-β1 stimulation of control and IPF fibroblasts  
• IPF fibroblasts demonstrated increased expression of the lncRNAs, 
LINC00960 and LINC01140 
• LINC00960 and LINC01140 were shown to be positive regulators of 
proliferation 
• LINC01140 was shown to be a negative regulator of IL-6 expression 
and protein release, possibly mediating the reduced inflammatory 
response observed in IPF fibroblasts 
• Differential gene expression of several mRNAs and lncRNAs was 
observed upon IL-1β stimulation of control fibroblasts 
• LncRNAs IL7AS and MIR3142HG demonstrated the highest 
upregulation upon IL-1β exposure in control fibroblasts 
• IL7AS was found to regulate IL-6 release in both control and IPF 
fibroblasts 
• MIR3142HG demonstrated a positive regulatory role for IL-8 and CCL2 
protein release in control fibroblasts but not IPF fibroblasts 
• Nintedanib had an inhibitory effect on PAI-1 release and cell 
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